<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        3010234405
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Celezon
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        RUXOLITINIB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        56
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        9004.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="The Arab Pharmaceutical Manufacturing PSC (Sahab) Co Ltd " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            The Arab Pharmaceutical Manufacturing PSC (Sahab) Co Ltd 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)	
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01XE18
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Celezon contains the active substance ruxolitinib.</p><p>Celezon is used to treat adult patients with an enlarged spleen or with symptoms related to myelofibrosis, a rare form of blood cancer.</p><p>Celezon is also used to treat adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.</p><p>Celezon is also used to treat patients 12 years of age and older and adults with graft-versus-host disease (GvHD). There are two forms of GvHD: an early form called acute GvHD that usually develops soon after the transplantation and can affect skin, liver and gastrointestinal tract, and a form called chronic GvHD, which develops later, usually weeks to months after the transplantation. Almost any organ can be affected by chronic GvHD.</p><p><strong>How Celezon works</strong></p><p>Enlargement of the spleen is one of the characteristics of myelofibrosis. Myelofibrosis is a disorder of the bone marrow, in which the marrow is replaced by scar tissue. The abnormal marrow can no longer produce enough normal blood cells and as a result the spleen becomes significantly enlarged. By blocking the action of certain enzymes (called Janus Associated Kinases), Celezon can reduce the size of the spleen in patients with myelofibrosis and relieve symptoms such as fever, night sweats, bone pain and weight loss in patients with myelofibrosis. Celezon can help reduce the risk of serious blood or vascular complications.</p><p>Polycythaemia vera is a disorder of the bone marrow, in which the marrow produce too many red blood cells. The blood becomes thicker as a result of the increased red blood cells. Celezon can relieve the symptoms, reduce spleen size and the volume of red blood cells produced in patients with polycythaemia vera by selectively blocking enzymes called Janus Associated Kinases (JAK1 and JAK2), thus potentially reducing the risk of serious blood or vascular complications. &nbsp;</p><p>Graft-versus-host disease is a complication which occurs after transplantation when specific cells (T cells) in the donor&rsquo;s graft (e.g. bone marrow) do not recognise the host cells/organs and attack them. By selectively blocking enzymes called Janus Associated Kinases (JAK1 and JAK2), Celezon reduces signs and symptoms of the acute and the chronic forms of graft-versus-host disease leading to disease improvement and survival of the transplanted cells.</p><p>If you have any questions about how Celezon works or why this medicine has been prescribed for you, ask your doctor.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Follow all your doctor&rsquo;s instructions carefully. They may differ from the general information contained in this leaflet.</p><p><strong>Do not take Celezon</strong></p><ul><li>&nbsp; &nbsp; If you are allergic to ruxolitinib or any of the other ingredients of this medicine (listed in section 6).</li><li>&nbsp; &nbsp; If you are pregnant or breast-feeding.</li></ul><p>If either of the above applies to you, tell your doctor who will then decide whether you should start treatment with Celezon.</p><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor or pharmacist before taking Celezon:</p><ul><li>&nbsp; &nbsp; If you have any infections. It may be necessary to treat your infection before starting Celezon. It is important that you tell your doctor if you have ever had tuberculosis or if you have been in close contact with someone who has or has had tuberculosis. Your doctor may perform tests to see if you have tuberculosis or any other infections. It is important that you tell your doctor if you have ever had hepatitis B.</li><li>&nbsp; &nbsp; If you have any kidney problems. Your doctor may need to prescribe a different dose of Celezon.</li><li>&nbsp; &nbsp; If you have or have ever had any liver problems. Your doctor may need to prescribe a different dose of Celezon.</li><li>&nbsp; &nbsp; If you are taking other medicines (see section &ldquo;Other medicines and Celezon&rdquo;).</li><li>&nbsp; &nbsp; If you have ever had tuberculosis.</li><li>&nbsp; &nbsp; If you have ever had skin cancer.</li></ul><p>Talk to your doctor or pharmacist during your treatment with Celezon:</p><ul><li>&nbsp; &nbsp; If you experience unexpected bruising and/or bleeding, unusual tiredness, shortness of breath during exercise or at rest, unusually pale skin, or frequent infections (these are signs of blood disorders).</li><li>&nbsp; &nbsp; If you experience fever, chills or other symptoms of infections.</li><li>&nbsp; &nbsp; If you experience chronic coughing with blood-tinged sputum, fever, night sweats and weight loss (these can be signs of tuberculosis).</li><li>&nbsp; &nbsp; If you have any of the following symptoms or if anyone close to you notices that you have any of these symptoms: confusion or difficulty thinking, loss of balance or difficulty walking, clumsiness, difficulty speaking, decreased strength or weakness on one side of your body, blurred and/or loss of vision. These may be signs of a serious brain infection and your doctor may suggest further testing and follow-up.</li><li>&nbsp; &nbsp; If you develop painful skin rash with blisters (these are signs of shingles).</li><li>&nbsp; &nbsp; If you notice skin changes. This may require further observation, as certain types of skin cancer (non-melanoma) have been reported.</li></ul><p><em>Blood tests </em></p><p>Before you start treatment with Celezon, your doctor will perform blood tests to determine the best starting dose for you. You will need to have further blood tests during treatment so that your doctor can monitor the amount of blood cells (white cells, red cells and platelets) in your body and assess how you are responding to the treatment and whether Celezon is having an unwanted effect on these cells. Your doctor may need to adjust the dose or stop treatment. Your doctor will carefully check if you have any signs or symptoms of infection before starting and during your treatment with Celezon. Your doctor will also regularly check the level of lipids (fat) in your blood.</p><p><strong>Children and adolescents</strong></p><p>This medicine is not intended for use by children or adolescents aged below 18 years, who have the disease myelofibrosis or polycythaemia vera because it has not been studied in this age group.</p><p>For the treatment of graft-versus-host disease, Celezon can be used in patients 12 years and older.</p><p><strong>Other medicines and Celezon</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>It is particularly important that you mention any of the following medicines containing any of the following active substances, as your doctor may need to adjust the Celezon dose for you.</p><p>The following may increase the risk of side effects with Celezon:</p><ul><li>&nbsp; &nbsp; Some medicines used to treat infections. These include medicines used to treat fungal diseases (such as ketoconazole, itraconazole, posaconazole, fluconazole and voriconazole), medicines used to treat certain types of bacterial infections (antibiotics such as clarithromycin, telithromycin, ciprofloxacin, or erythromycin), medicines to treat viral infections, including HIV infection/AIDS (such as amprenavir, atazanavir, indinavir, lopinavir/ritonavir, nelfinavir, ritonavir, saquinavir), medicines to treat hepatitis C (boceprevir, telaprevir).</li><li>&nbsp; &nbsp; Nefazodone, a medicine to treat depression.</li><li>&nbsp; &nbsp; Mibefradil or diltiazem, medicines to treat hypertension and chronic angina pectoris.</li><li>&nbsp; &nbsp; Cimetidine, a medicine to treat heartburn.</li></ul><p>The following may reduce the effectiveness of Celezon:</p><ul><li>&nbsp; &nbsp; Avasimibe, a medicine to treat heart disease.</li><li>&nbsp; &nbsp; Phenytoin, carbamazepine or phenobarbital and other anti-epileptics used to stop seizures or fits.</li><li>&nbsp; &nbsp; Rifabutin or rifampicin, medicines used to treat tuberculosis (TB).</li><li>&nbsp; &nbsp; St. John&rsquo;s wort (Hypericum perforatum), a herbal product used to treat depression.</li></ul><p><strong>While you are taking Celezon</strong></p><p>You should never start a new medicine without checking first with the doctor who prescribed Celezon. This includes prescription medicines, non-prescription medicines and herbal or alternative medicines.</p><p><strong>Pregnancy and breast-feeding </strong></p><p>Do not take Celezon during pregnancy. Talk to your doctor about how to take appropriate measures to avoid becoming pregnant during your treatment with Celezon.</p><p>Do not breast-feed while taking Celezon. Tell your doctor if you are breast-feeding.</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p><strong>Driving and using machines </strong></p><p>If you experience dizziness after taking Celezon, do not drive or use machines.</p><p><strong>Celezon </strong><strong>contains lactose and sodium</strong></p><p>Celezon contains lactose. Each tablet of Celezon 5 mg, 10 mg, 15 mg, 20 mg and 25 mg Tablets contains 71.2 mg, 142.4 mg, 213.6 mg, 284.8 mg or 356 mg lactose; respectively. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p><p>Celezon contains sodium. Each tablet of Celezon 5 mg, 10 mg, 15 mg, 20 mg and 25 mg Tablets contains 0.24 mg, 0.49 mg, 0.73 mg, 0.98 mg or 1.22 mg sodium; respectively. This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>The dose of Celezon depends on the patient&rsquo;s blood cell count. Your doctor will measure the amount of blood cells in your body and find the best dose for you, particularly if you have liver or kidney problems.</p><ul><li>&nbsp; &nbsp; The recommended starting dose in myelofibrosis is 5 mg twice daily, 10 mg twice daily, 15 mg twice daily or 20 mg twice daily, depending on your blood cell count.</li><li>&nbsp; &nbsp; The recommended starting dose in polycythaemia vera and in graft-versus-host disease is 10 mg twice daily.</li><li>&nbsp; &nbsp; The maximum dose is 25 mg twice daily.</li></ul><p>Your doctor will always tell you exactly how many Celezon tablets to take.</p><p>During the treatment your doctor may recommend a lower or higher dose to you if the results of blood tests show that this is necessary, if you have problems with your liver or kidneys, or if you also need treatment with certain other medicines.</p><p>If you receive dialysis, take either one single dose or two separate doses of Celezon only on dialysis days, after the dialysis has been completed. Your doctor will tell you if you should take one or two doses and how many tablets to take for each dose.</p><p>You should take Celezon every day at the same time, either with or without food.</p><p>You should continue taking Celezon for as long as your doctor tells you to. This is a long-term treatment.</p><p>Your doctor will regularly monitor your condition to make sure that the treatment is having the desired effect.</p><p>If you have questions about how long to take Celezon, talk to your doctor or pharmacist.</p><p>If you experience certain side effects (e.g. blood disorders), your doctor might need to change the amount of Celezon you have to take or tell you to stop taking Celezon for a while.</p><p><strong>If you take more </strong><strong>Celezon </strong><strong>than you should</strong></p><p>If you accidentally take more Celezon than your doctor prescribed, contact your doctor or pharmacist immediately.</p><p><strong>If you forget to take </strong><strong>Celezon</strong></p><p>If you forgot to take Celezon simply take your next dose at the scheduled time. Do not take a double dose to make up for a forgotten dose.</p><p><strong>If you stop taking </strong><strong>Celezon</strong></p><p>If you interrupt your treatment with Celezon your symptoms related to myelofibrosis or polycythaemia vera may come back. In graft-versus-host disease, a reduction in your dose or stopping your treatment with Celezon is possible if you respond to treatment and your doctor will supervise this procedure. Therefore, you should not stop taking Celezon or change the dose without discussing it with your doctor.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Most of the side effects of ruxolitinib are mild to moderate and will generally disappear after a few days to a few weeks of treatment.</p><p><strong><em>Myelofibrosis and polycythaemia vera</em></strong></p><p><strong>Some side effects could be serious.</strong></p><p><strong>Seek medical help immediately prior to taking the next scheduled dose if you experience the following serious side effects: </strong></p><p><em>Very common (may affect more than 1 in 10 people)</em></p><ul><li>&nbsp; &nbsp; Any sign of bleeding in the stomach or intestine, such as passing black or bloodstained stools, or vomiting blood</li><li>&nbsp; &nbsp; Unexpected bruising and/or bleeding, unusual tiredness, shortness of breath during exercise or at rest, unusually pale skin, or frequent infections (possible symptoms of blood disorders)</li><li>&nbsp; &nbsp; Painful skin rash with blisters (possible symptoms of shingles (herpes zoster))</li><li>&nbsp; &nbsp; Fever, chills or other symptoms of infections</li><li>&nbsp; &nbsp; Low level of red blood cells (anaemia), low level of white blood cells (neutropenia) or low level of platelets (thrombocytopenia)</li></ul><p><em>Common (may affect up to 1 in 10 people):</em></p><ul><li>&nbsp; &nbsp; Any sign of bleeding in the brain, such as sudden altered level of consciousness, persistent headache, numbness, tingling, weakness or paralysis</li></ul><p><strong>Other side effects with ruxolitinib</strong></p><p>Other possible side effects include the following listed below. If you experience these side effects talk to your doctor or pharmacist.</p><p><em>Very common (may affect more than 1 in 10 people):</em></p><ul><li>&nbsp; &nbsp; High level of cholesterol or fat in the blood (hypertriglyceridaemia)</li><li>&nbsp; &nbsp; Abnormal liver function test results</li><li>&nbsp; &nbsp; Dizziness</li><li>&nbsp; &nbsp; Headache</li><li>&nbsp; &nbsp; Urinary tract infections</li><li>&nbsp; &nbsp; Weight gain</li><li>&nbsp; &nbsp; Fever, cough, difficult or painful breathing, wheezing, pain in chest when breathing (possible symptoms of pneumonia)</li><li>&nbsp; &nbsp; High blood pressure (hypertension), which may also be the cause of dizziness and headaches</li><li>&nbsp; &nbsp; Constipation</li><li>&nbsp; &nbsp; High level of lipase in the blood</li></ul><p><em>Common (may affect up to 1 in 10 people):</em></p><ul><li>&nbsp; &nbsp; Reduced number of all three types of blood cells &ndash; red blood cells, white blood cells, and platelets (pancytopenia)</li><li>&nbsp; &nbsp; Frequently passing wind (flatulence)</li></ul><p><em>Uncommon (may affect up to 1 in 100 people): </em></p><ul><li>&nbsp; &nbsp; Tuberculosis</li><li>&nbsp; &nbsp; Recurrence of hepatitis B infection (which can cause yellowing of the skin and eyes, dark brown-colored urine, right-sided stomach pain, fever and feeling nauseous or being sick)</li></ul><p><strong><em>Graft-versus-host disease (GvHD) </em></strong></p><p><strong>Some side effects could be serious.</strong></p><p><strong>Seek medical help immediately prior to taking the next scheduled dose if you experience the following serious side effects: </strong></p><p><em>Very common (may affect more than 1 in 10 people): </em></p><ul><li>&nbsp; &nbsp; Fever, pain, redness, and/or difficulty breathing (possible symptoms of an infection with the cytomegalovirus (cytomegalovirus infection))</li><li>&nbsp; &nbsp; Fever, pain when urinating (possible symptoms of a urinary tract infection)</li><li>&nbsp; &nbsp; Fast heart rate, fever, confusion and rapid breathing (possible symptoms of sepsis, which is a serious condition that occurs in response to an infection that causes widespread inflammation)</li><li>&nbsp; &nbsp; Tiredness, fatigue, pale skin (possible symptoms of anaemia which is caused by low level of red blood cells), frequent infections, fever, chills, sore throat or mouth ulcers due to infections (possible symptoms of neutropenia which is caused by low level of white blood cells), spontaneous bleeding or bruising (possible<strong> </strong>symptoms of thrombocytopenia which is caused by low levels of platelets)&nbsp;</li><li>&nbsp; &nbsp; Low counts of all three types of blood cells - red blood cells, white blood cells, and platelets (pancytopenia) &nbsp;</li></ul><p><strong>Other side effects </strong></p><p>Other possible side effects include the following listed below. If you experience these side effects talk to your doctor or pharmacist.</p><p><em>Very common (may affect more than 1 in 10 people): </em></p><ul><li>&nbsp; &nbsp; High level of cholesterol (hypercholesterolaemia)&nbsp;</li><li>&nbsp; &nbsp; Headache&nbsp;</li><li>&nbsp; &nbsp; High blood pressure (hypertension)&nbsp;</li><li>&nbsp; &nbsp; Feeling sick (nausea)&nbsp;</li><li>&nbsp; &nbsp; Abnormal liver function test results&nbsp;</li><li>&nbsp; &nbsp; Increased blood level of enzyme from muscle potentially indicating muscle damage and/or muscle breakdown (increased blood creatine phosphokinase)&nbsp;</li><li>&nbsp; &nbsp; Increased blood level of creatinine, a substance normally eliminated by the kidneys into the urine, which may mean that your kidneys are not functioning properly (increased blood creatinine)</li></ul><p><em>Common (may affect up to 1 in 10 people): </em></p><ul><li>&nbsp; &nbsp; Fever, pain, redness, and/or difficulty breathing (possible symptoms of infection with BK virus)</li><li>&nbsp; &nbsp; Weight gain&nbsp;</li><li>&nbsp; &nbsp; Constipation</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Store below 30&deg;C.</p><p>Store in the original package.</p><p>Do not use this medicine after the expiry date which is stated on the package after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Do not use this medicine if you notice any visible signs of deterioration.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Celezon contains</strong></p><p>The active substance is ruxolitinib phosphate.</p><p>Each tablet of Celezon 5 mg Tablets contains 6.6 mg ruxolitinib phosphate equivalent to 5 mg ruxolitinib. &nbsp;</p><p>Each tablet of Celezon 10 mg Tablets contains 13.2 mg ruxolitinib phosphate equivalent to 10 mg ruxolitinib.</p><p>Each tablet of Celezon 15 mg Tablets contains 19.8 mg ruxolitinib phosphate equivalent to 15 mg ruxolitinib. &nbsp;</p><p>Each tablet of Celezon 20 mg Tablets contains 26.4 mg ruxolitinib phosphate equivalent to 20 mg ruxolitinib. &nbsp;</p><p>Each tablet of Celezon 25 mg Tablets contains 33 mg ruxolitinib phosphate equivalent to 25 mg ruxolitinib.</p><p>The other ingredients are lactose, microcrystalline cellulose, hydroxypropyl cellulose, povidone, sodium starch glycolate, colloidal silicon dioxide and magnesium stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Celezon 5 mg Tablets are white to off-white round-shaped tablets, embossed with "R4" on one side in aluminum-aluminum blisters.

Celezon 10 mg Tablets are white to off-white round-shaped tablets, embossed with "R3" on one side in aluminum-aluminum blisters.

Celezon 15 mg Tablets are white to off-white oval-shaped tablets, embossed with "R2" on one side in aluminum-aluminum blisters.  

Celezon 20 mg Tablets are white to off-white modified capsule-shaped tablets, embossed with "R1" on one side in aluminum-aluminum blisters.  

Celezon 25 mg Tablets are white to off-white oval-shaped tablets, embossed with "R5" on one side in aluminum-aluminum blisters.

Pack sizes:

    Celezon 5 mg, 10 mg, 15 mg and 20 mg Tablets: 56 Tablets.  
    Celezon 25 mg Tablets: 60 Tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder and Batch releaser</strong></p><p>Jazeera Pharmaceutical Industries<br />Al-Kharj Road<br />P.O. Box 106229<br />Riyadh 11666, Saudi Arabia<br />Tel: + (966-11) 8107023, + (966-11) 2142472<br />Fax: + (966-11) 2078170<br />e-mail: SAPV@hikma.com</p><p>&nbsp;</p><p><strong>Bulk manufacturer</strong></p><p>The Arab Pharmaceutical Manufacturing PSC<br />Sahab<br />Industrial City<br />P.O. Box 41<br />Amman 11512, Jordan<br />Tel: + (962-6) 4023916<br />Fax: + (962-6) 4023917</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects, you can also help provide more information on the safety of this medicine.</p><ul><li>&nbsp; &nbsp; Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><ul><li>&nbsp; &nbsp; Other GCC States</li></ul><p>Please contact the relevant competent authority.</p><ul><li>&nbsp; &nbsp; United Arab of Emirates</li></ul><p>Pharmacovigilance &amp; Medical Device Section</p><p>P.O. Box: 1853</p><p>Tel: 80011111</p><p>Email: pv@mohap.gov.ae</p><p>Drug Department</p><p>Ministry of Health &amp; Prevention</p><p>Dubai</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 11/2022; version number Un1.0.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي سيليزون على المادة الفعالة روكسوليتينيب.</p><p>&nbsp;</p><p dir="RTL">يُستخدم سيليزون لعلاج المرضى البالغين المصابين بتضخم الطحال أو ذوي الأعراض المرتبطة بتليف النقي، وهو شكل نادر لسرطان الدم.</p><p>&nbsp;</p><p dir="RTL">يُستخدم سيليزون أيضاً لعلاج المرضى البالغين الذين يعانون من كثرة الكريات الحمراء الحقيقية الذين لا يستجيبون للهيدروكسي يوريا أو لا يتحملونه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستخدم سيليزون أيضاً لعلاج المرضى الذين تبلغ أعمارهم 12 عاماً فأكثر والبالغين المصابين بمرض الطُعم حيال الثَوي. ثمة نوعان من مرض الطُعم حيال الثَوي: نوع مبكر يُسمى مرض الطُعم حيال الثَوي الحاد الذي يتطور عادة بعد وقت قصير من الزرع ويمكن أن يؤثر على الجلد، الكبد والجهاز الهضمي، ونوع يُسمى مرض الطُعم حيال الثَوي المزمن، والذي يتطور لاحقاً، عادةً بعد أسابيع إلى شهور من الزرع. يمكن أن يُصاب أي عضو تقريباً بمرض الطُعم حيال الثَوي المزمن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>طريقة عمل سيليزون</strong></p><p dir="RTL">يعد تضخم الطحال أحد خصائص مرض تليف النقي. تليف النقي هو اضطراب يصيب نخاع العظم، حيث يتم استبدال النخاع بنسيج ندبي. لا يعد بإمكان النخاع الطبيعي إنتاج ما يكفي من خلايا الدم الطبيعية ونتيجة لذلك يصبح الطحال متضخماً بشكل كبير. من خلال حصر عمل إنزيمات معينة (تسمى إنزيمات كيناز المرتبطة بجانوس)، بإمكان سيليزون تقليل حجم الطحال في مرضى تليف النقي وتخفيف الأعراض مثل الحمى، التعرق الليلي، ألم العظام وفقدان الوزن في مرضى تليف النقي. بإمكان سيليزون المساعدة في تقليل خطر مضاعفات دموية ووعائية خطيرة.</p><p>&nbsp;</p><p dir="RTL">كثرة الكريات الحمراء الحقيقية هو اضطراب يصيب نخاع العظم، حيث يقوم فيه النخاع بإنتاج خلايا دم حمراء أكثر من اللازم. يصبح الدم أكثر سمكاً نتيجة لزيادة خلايا الدم الحمراء. بإمكان سيليزون تخفيف الأعراض، تقليل حجم الطحال وعدد خلايا الدم الحمراء الناتجة لدى مرضى كثرة الكريات الحمراء الحقيقية من خلال حصر إنزيمات معينة بشكل انتقائي تسمى إنزيمات كيناز المرتبطة بجانوس (كيناز المرتبطة بجانوس 1وكيناز المرتبطة بجانوس 2)، وبالتالي احتمالية تقليل خطر مضاعفات دموية أو وعائية خطيرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">مرض الطُعم حيال الثَوي هو أحد المضاعفات التي تحدث بعد الزرع عندما لا تتعرف خلايا معينة (الخلايا التائية) في طُعم المتبرع (مثل، نخاع العظم) على الخلايا/الأعضاء المضيفة وتهاجمها. يُخفِّض سيليزون علامات وأعراض أنواع مرض الطُعم حيال الثَوي الحاد والمزمن من خلال حصر إنزيمات معينة بشكل انتقائي تسمى إنزيمات كيناز المرتبطة بجانوس (كيناز المرتبطة بجانوس 1وكيناز المرتبطة بجانوس 2)، وهو ما يؤدي إلى تحسّن حالة المريض وبقاء الخلايا المزروعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">اسأل طبيبك إذا كانت لديك أي أسئلة عن طريقة عمل سيليزون أو سبب وصف هذا الدواء لك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">اتبع كل تعليمات طبيبك بعناية. قد تختلف عن المعلومات العامة الواردة في هذه النشرة.</p><p>&nbsp;</p><p dir="RTL"><strong>لا تتناول سيليزون</strong></p><ul dir="rtl"><li>&nbsp; &nbsp; إذا كنت تعاني من تحسس لروكسوليتينيب أو لأي من المواد الأخرى المستخدمة في تركيبة هذا الدواء (المذكورة في القسم 6).</li><li>&nbsp; &nbsp; إذا كنتِ حاملاً أو مرضعاً.</li></ul><p>&nbsp;</p><p dir="RTL">إذا كان أي من الحالتين السابقتين ينطبق عليك، فأخبر طبيبك الذي سيقرر إذا ما كان يجب عليك بدء العلاج بسيليزون.</p><p>&nbsp;</p><p dir="RTL"><strong>الاحتياطات والتحذيرات </strong></p><p dir="RTL">تحدث مع طبيبك أو الصيدلي قبل تناول سيليزون:</p><ul dir="rtl"><li>&nbsp; &nbsp; إذا كنت تعاني من أي عدوى. قد يلزم علاج العدوى قبل بدء العلاج باستخدام سيليزون. من المهم أن تخبر طبيبك إذا أُصبت سابقاً بمرض السل. أو إذا كنت على صلة وثيقة بشخص مصاب أو كان أصيب سابقاً بمرض السل&nbsp; قد يقوم طبيبك بإجراء اختبارات لمعرفة ما إذا كنت مصاباً بمرض السل أو أي عدوى أخرى. من المهم أن تخبر طبيبك أنه سبق أن أصبت بالالتهاب الكبدي ب.</li><li>&nbsp; &nbsp; إذا كنت تعاني من أي مشاكل في الكلى. قد يحتاج طبيبك إلى وصف جرعة مختلفة من سيليزون.</li><li>&nbsp; &nbsp; إذا كنت تعاني أو عانيت سابقاً من أي مشاكل في الكبد. قد يحتاج طبيبك إلى وصف جرعة مختلفة من سيليزون.</li><li>&nbsp; &nbsp; إذا كنت تتناول أدوية أخرى (انظر قسم &quot;الأدوية الأخرى وسيليزون&quot;).</li><li>&nbsp; &nbsp; إذا أصبت سابقاً بالسل.</li><li>&nbsp; &nbsp; إذا أصبت سابقاً بسرطان الجلد.</li></ul><p dir="RTL">استشر طبيبك أو الصيدلي أثناء العلاج باستخدام سيليزون:</p><ul dir="rtl"><li>&nbsp; &nbsp; إذا عانيت من تكدم غير متوقع و/أو نزف، تعب غير معتاد، ضيق نفس أثناء ممارسة التمارين أو في الراحة، بشرة شاحبة على نحو غير معتاد أو عدوى متكررة (هذه هي علامات اضطرابات الدم).</li><li>&nbsp; &nbsp; إذا عانيت من حمى، قشعريرة أو أعراض عدوى أخرى.</li><li>&nbsp; &nbsp; إذا عانيت من سعال مزمن مع بلغم ملوث بالدم، حمى، تعرق ليلي وفقدان الوزن (قد تكون هذه علامات الإصابة بمرض السل).</li><li>&nbsp; &nbsp; إذا عانيت من أي من الأعراض التالية أو إذا لاحظ أي شخص قريب منك أنك مصاب بأي من هذه الأعراض: التشوش أو صعوبة في التفكير، فقدان التوازن أو صعوبة في السير، الدوار، الكُلال، صعوبة في الكلام، أو انخفاض القوة أو الضعف في أحد جانبي الجسم، عدم وضوح الرؤية و/أو فقدانها. قد تكون هذه علامات لعدوى خطيرة في الدماغ وقد يقترح طبيبك مزيداً من الاختبارات والمتابعة.</li><li>&nbsp; &nbsp; إذا أصبت بطفح جلدي مؤلم مع وجود بثور (هذه علامات الحزام الناري).</li><li>&nbsp; &nbsp; إذا لاحظت تغيرات جلدية. قد يتطلب ذلك مزيداً من الملاحظة، حيث تم الإبلاغ عن الإصابة بأنواع معينة من سرطان الجلد (غير القتامي).</li></ul><p dir="RTL"><em>اختبارات الدم </em></p><p dir="RTL">قبل أن تبدأ العلاج بسيليزون، سيقوم طبيبك بإجراء اختبارات الدم لتحديد أفضل جرعة بداية لك. ستحتاج إلى إجراء المزيد من اختبارات الدم أثناء العلاج حتى يتمكن طبيبك من مراقبة مقدار خلايا الدم (الخلايا البيضاء، الخلايا الحمراء والصفائح الدموية) في جسمك وتقييم مدى استجابتك للعلاج وإذا ما كان لسيليزون آثار غير مرغوبة على هذه الخلايا. قد يحتاج طبيبك إلى تعديل الجرعة أو إيقاف العلاج. سيفحص طبيبك بعناية إذا ما كنت مصاباً بأي علامات أو أعراض عدوى قبل بدء العلاج بسيليزون وأثنائه. سيقوم طبيبك أيضاً بفحص مستوى الدهون (الشحوم) في دمك بانتظام.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">هذا الدواء غير مخصص للاستخدام لدى الأطفال أو المراهقين بعمر أقل من 18 عاماً، الذين يعانون من تليف النقي أو كثرة الكريات الحمراء الحقيقية نظراً لعدم وجود دراسات خاصة به في هذه الفئة العمرية.</p><p dir="RTL">لعلاج داء&nbsp;الطعم&nbsp;حيال الثَّويّ، يمكن استخدام سيليزون في المرضى بعمر 12 عاماً فما فوق.</p><p dir="RTL"><strong>الأدوية الأخرى وسيليزون</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تأخذ، أخذت مؤخراً، أو قد تأخذ أي أدوية أخرى.</p><p dir="RTL">من المهم بصفة خاصة أن تذكر أي من الأدوية التالية التي تحتوي على أي من المواد الفعالة التالية، حيث قد يرغب طبيبك في تعديل جرعة سيليزون التي تتناولها.</p><p dir="RTL">قد تتسبب الأدوية التالية في زيادة خطر الإصابة بالآثار الجانبية مع تناول سيليزون:</p><ul dir="rtl"><li>&nbsp; &nbsp; بعض الأدوية المستخدمة لعلاج العدوى. تشمل الأدوية المستخدمة لعلاج الأمراض الفطرية (مثل كيتوكونازول، إيتراكونازول، بوساكونازول، فلوكونازول وفوريكونازول)، والأدوية المستخدمة لعلاج أنواع معينة من العدوى البكتيرية (المضادات الحيوية مثل كلاريثروميسين، تيليثروميسين، سيبروفلوكساسين أو إيريثروميسين)، والأدوية المستخدمة لعلاج العدوى الفيروسية، بما في ذلك فيروس نقص المناعة البشرية/الإيدز (مثل أمبرينافير، أتازانافير، إيندينافير، لوبينافير/ ريتونافير، نيلفينافير، ريتونافير، ساكينافير)، والأدوية المستخدمة لعلاج الالتهاب الكبدي ج (بوسيبريفير، تيلابريفير).</li><li>&nbsp; &nbsp; نيفازودون، وهو دواء لعلاج الاكتئاب.</li><li>&nbsp; &nbsp; ميبفراديل أو ديلتيازيم، أدوية لعلاج ارتفاع ضغط الدم والذبحة الصدرية المزمنة.</li><li>&nbsp; &nbsp; سيميتيدين، دواء لعلاج حرقة المعدة.</li></ul><p dir="RTL">قد تقلل الأدوية التالية من فاعلية سيليزون:</p><ul dir="rtl"><li>&nbsp; &nbsp; أفاسيميب، دواء لعلاج أمراض القلب.</li><li>&nbsp; &nbsp; فينيتوين، كاربامازيبين أو فينوباربيتال ومضادات الصرع الأخرى المستخدمة لإيقاف الاختلاجات أو النوبات التشنجية.</li><li>&nbsp; &nbsp; ريفابوتين أو ريفامبيسين، أدوية تستخدم لعلاج مرض السل.</li><li>&nbsp; &nbsp; نبتة سانت جونز (حشيشة القلب)، مستحضر عشبي يُستخدم لعلاج الاكتئاب.</li></ul><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>أثناء تناول سيليزون</strong></p><p dir="RTL">يجب ألا تبدأ مطلقاً في استخدام دواء جديد بدون مراجعة الطبيب الذي وصف لك سيليزون أولاً. يشمل ذلك أدوية الوصفة الطبية، الأدوية بدون وصفة طبية والأدوية والبدائل العشبية.</p><p>&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة </strong></p><p dir="RTL">لا تتناولي سيليزون أثناء الحمل. استشيري طبيبك حول كيفية اتخاذ التدابير الملائمة لتجنب الحمل أثناء العلاج باستخدام سيليزون.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تُرضعي أثناء تناول سيليزون. أخبري طبيبك إذا كنتِ ترضعين رضاعة طبيعية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">استشيري طبيبك أو الصيدلي إذا كنتِ حاملاً أو مرضعاً، تعتقدين بأنكِ حامل أو تخططين لذلك قبل تناول هذا الدواء.</p><p>&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات </strong></p><p dir="RTL">لا تقم بالقيادة أو استخدام الآلات إذا شعرت بالدوخة أثناء تناول سيليزون.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي سيليزون على اللاكتوز والصوديوم</strong><strong> </strong></p><p dir="RTL">يحتوي سيليزون على اللاكتوز. يحتوي كل قرص من سيليزون 5 ملغم، 10 ملغم، 15 ملغم، 20 ملغم و25 ملغم أقراص على 71,2 ملغم، 142.4 ملغم، 213.6 ملغم، 284.8 ملغم أو 356 ملغم لاكتوز؛ على التوالي. إذا أخبرك طبيبك بأن لديك عدم تحمل لبعض السكريات، فتواصل مع طبيبك قبل تناول هذا المستحضر الدوائي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي سيليزون على الصوديوم. يحتوي كل قرص من سيليزون 5 ملغم، 10 ملغم، 15 ملغم، 20 ملغم و25 ملغم أقراص على 0,24 ملغم، 0.49 ملغم، 0,73 ملغم، 0.98 ملغم أو 1.22 ملغم صوديوم؛ على التوالي. يحتوي هذا الدواء على أقل من 1 ملمول صوديوم (23 ملغم) لكل قرص، وبذلك يعتبر &rsquo;خالٍ من الصوديوم&lsquo; بشكل أساسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قم دائماً بتناول هذا الدواء تماماً كما وصفه لك طبيبك أو الصيدلي. استشر طبيبك أو الصيدلي إذا لم تكن متأكداً.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تعتمد جرعة سيليزون على عدد خلايا الدم الحمراء للمريض. سيقوم طبيبك بقياس مقدار خلايا الدم الحمراء في جسمك لمعرفة أفضل جرعة لك، خاصة إذا كنت تعاني من مشاكل في الكبد أو الكلى.</p><ul dir="rtl"><li>&nbsp; &nbsp; تبلغ جرعة البداية الموصى بها لمرض تليف النقي 5 ملغم مرتين يومياً، 10 ملغم مرتين يومياً، 15 ملغم مرتين يومياً أو 20 ملغم مرتين يومياً، تبعاً لعدد خلايا الدم لديك.</li><li>&nbsp; &nbsp; تبلغ جرعة البداية الموصى بها لمرض كثرة الكريات الحمراء الحقيقية وداء&nbsp;الطعم&nbsp;حيال الثَّويّ 10 ملغم مرتين يومياً.</li><li>&nbsp; &nbsp; تبلغ الجرعة القصوى 25 ملغم مرتين يومياً.</li></ul><p dir="RTL">سيبلغك طبيبك دائماً بالعدد المحدد لأقراص سيليزون التي يجب تناولها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يوصي الطبيب أثناء العلاج بجرعة أقل أو أعلى لك إذا أظهرت نتائج اختبارات الدم ضرورة ذلك، إذا كنت تعاني من مشاكل في الكبد أو الكلى، أو إذا كنت أيضاً بحاجة لعلاج مع أدوية أخرى معينة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تخضع للغسيل الكلوي، فتناول جرعة واحدة أو جرعتين منفصلتين من سيليزون فقط في أيام الغسيل الكلوي، بعد استكمال الغسيل الكلوي. سيخبرك طبيبك إذا كان يجب عليك تناول جرعة واحدة أو جرعتين وعدد الأقراص في كل جرعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عليك تناول سيليزون كل يوم في نفس الوقت، مع الطعام أو بدونه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب أن تستمر في تناول سيليزون طوال المدة التي يحددها لك طبيبك. هذا العلاج طويل المدى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيقوم طبيبك بمراقبة حالتك بشكل دوري للتأكد من تحقيق العلاج للتأثير المرغوب فيه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك أسئلة بشأن مدة استخدام سيليزون، فتحدث مع طبيبك أو الصيدلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا عانيت من آثار جانبية معينة (مثل اضطرابات الدم)، فقد يحتاج طبيبك إلى تغيير كمية سيليزون التي يجب عليك تناولها أو إخبارك بالتوقف عن تناول سيليزون لفترة معينة.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا تناولت </strong><strong>سيليزون أكثر من اللازم</strong></p><p dir="RTL">إذا تناولت جرعة أكبر من الجرعة التي حددها لك الطبيب من سيليزون عن طريق الخطأ، فتواصل مع طبيبك أو الصيدلي فوراً.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا نسيت تناول </strong><strong>سيليزون</strong></p><p dir="RTL">إذا نسيت تناول سيليزون، فقم ببساطة بتناول جرعتك التالية في الوقت المحدد. لا تقم بتناول جرعة مضاعفة لتعويض الجرعة المنسية.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن تناول </strong><strong>سيليزون</strong></p><p dir="RTL">إذا أوقفت علاجك باستخدام سيليزون، فقد تعود الأعراض المرتبطة بمرض تليف النقي أو مرض كثرة الكريات الحمراء الحقيقية لديك. في داء&nbsp;الطعم&nbsp;حيال الثَّويّ، &nbsp;من الممكن تخفيض جرعتك أو إيقاف علاجك مع سيليزون إذا استجبت للعلاج وسيشرف طبيبك على هذا الإجراء. لذلك، يجب عليك عدم التوقف عن تناول سيليزون أو تغيير الجرعة دون مناقشة ذلك مع طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك أية أسئلة إضافية حول استخدام هذا الدواء، استشر طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب هذا الدواء آثاراً جانبية إلا أنه ليس بالضرورة أن تحدث لدى جميع مستخدمي هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أغلب الآثار الجانبية لروكسوليتينيب تتراوح ما بين خفيفة إلى متوسطة وستزول عادةً بعد أيام قليلة إلى أسابيع قليلة من العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>تليف النقي وكثرة الكريات الحمراء الحقيقية</em></strong></p><p dir="RTL"><strong>قد تكون بعض الآثار الجانبية خطيرة. </strong></p><p dir="RTL"><strong>اطلب المساعدة الطبية فوراً قبل تناول الجرعة المقررة التالية إذا كنت تعاني من الآثار الجانبية الخطيرة التالية:</strong></p><p dir="RTL"><em>شائعة جداً (قد تؤثر في أكثر من شخص واحد من كل 10 أشخاص):</em></p><ul dir="rtl"><li>&nbsp; &nbsp; أي علامة لحدوث نزف في المعدة أو الأمعاء، مثل براز أسود أو ملطخ بالدماء، أو تقيؤ الدم</li><li>&nbsp; &nbsp; تكدم غير متوقع و/أو نزف، تعب غير معتاد، ضيق نفس أثناء ممارسة التمارين أو في الراحة، بشرة شاحبة على نحو غير معتاد أو عدوى متكررة (أعراض محتملة لاضطرابات الدم)</li><li>&nbsp; &nbsp; طفح جلدي مؤلم مع وجود بثور (أعراض محتملة للحزام الناري (الهربس النطاقي)</li><li>&nbsp; &nbsp; حمى، قشعريرة أو أعراض عدوى أخرى</li><li>&nbsp; &nbsp; انخفاض مستوى خلايا الدم الحمراء (فقر الدم)، انخفاض مستوى خلايا الدم البيضاء (قلة العدلات) أو انخفاض مستوى الصفائح الدموية (قلة الصفيحات)</li></ul><p dir="RTL"><em>شائعة (قد تؤثر فيما يصل إلى شخص واحد من كل 10 أشخاص):</em></p><ul dir="rtl"><li>&nbsp; &nbsp; أي علامة لحدوث نزف في الدماغ، مثل تغير مفاجئ في مستوى الوعي، صداع مستمر، تنميل، وخز، ضعف أو شلل</li></ul><p>&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الأخرى مع روكسوليتينيب </strong></p><p dir="RTL">تشمل الآثار الجانبية المحتملة الأخرى ما يلي مدرج أدناه. إذا عانيت من هذه الآثار الجانبية، تحدث إلى طبيبك أو الصيدلي.</p><p dir="RTL"><em>شائعة جداً (قد تؤثر في أكثر من شخص واحد من كل 10 أشخاص):</em></p><ul dir="rtl"><li>&nbsp; &nbsp; ارتفاع مستوى الكوليسترول أو الدهون في الدم (فرط ثلاثي جليسيريد الدم)</li><li>&nbsp; &nbsp; نتائج اختبارات وظائف كبد غير طبيعية</li><li>&nbsp; &nbsp; دوخة</li><li>&nbsp; &nbsp; صداع</li><li>&nbsp; &nbsp; التهابات المسالك البولية</li><li>&nbsp; &nbsp; زيادة الوزن</li><li>&nbsp; &nbsp; حمى، سعال، صعوبة أو ألم أثناء التنفس، أزيز، ألم في الصدر عند التنفس (أعراض محتملة للالتهاب الرئوي)</li><li>&nbsp; &nbsp; ارتفاع ضغط الدم (فرط ضغط الدم)، ما قد يسبب أيضاً حدوث دوخة أو صداع</li><li>&nbsp; &nbsp; إمساك</li><li>&nbsp; &nbsp; ارتفاع مستوى إنزيم الليباز في الدم</li></ul><p>&nbsp;</p><p dir="RTL"><em>شائعة (قد تؤثر فيما يصل إلى شخص واحد من كل 10 أشخاص):</em></p><ul dir="rtl"><li>&nbsp; &nbsp; انخفاض عدد أنواع خلايا الدم الثلاثة - خلايا الدم الحمراء، خلايا الدم البيضاء، والصفائح الدموية (قلة الكريات الشاملة)</li><li>&nbsp; &nbsp; الغازات المتكررة (تطبل البطن)</li></ul><p dir="RTL"><em>غير شائعة (قد تؤثر فيما يصل إلى شخص واحد من كل 100 شخص): </em></p><ul dir="rtl"><li>&nbsp; &nbsp; السل</li><li>&nbsp; &nbsp; تكرار الإصابة بالتهاب الكبد ب (الذي يمكن أن يسبب اصفرار الجلد والعينين، خروج البول بلون بني داكن، آلاماً في الجانب الأيمن من المعدة، حمى وشعوراً بالغثيان أو القيء)</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>مرض الطُعم حيال الثَوي </em></strong></p><p dir="RTL"><strong>قد تكون بعض الآثار الجانبية خطيرة. </strong></p><p dir="RTL"><strong>اطلب المساعدة الطبية فوراً قبل تناول الجرعة المقررة التالية إذا كنت تعاني من الآثار الجانبية الخطيرة التالية:</strong></p><p dir="RTL"><em>شائعة جداً (قد تؤثر في أكثر من شخص واحد من كل 10 أشخاص): </em></p><ul dir="rtl"><li>&nbsp; &nbsp; الحمى، الألم، الاحمرار، و/أو صعوبة التنفس (الأعراض المحتملة للإصابة بعدوى الفيروس المضخِّم للخلايا)</li><li>&nbsp; &nbsp; الحمى، الألم عند التبول (الأعراض المحتملة لالتهاب المسالك البولية)</li><li>&nbsp; &nbsp; تسارع نبضات القلب، الحمى، التشوش والتنفس السريع (الأعراض المحتملة للإنتان، وهي حالة خطيرة تحدث استجابةً لعدوى تسبب التهاباً واسع النطاق)</li><li>&nbsp; &nbsp; التعب، الإرهاق، شحوب الجلد (الأعراض المحتملة لفقر الدم الناجم عن انخفاض مستوى خلايا الدم الحمراء)، حالات العدوى المتكررة، الحمى، القشعريرة، التهاب الحلق، أو تقرّحات الفم بسبب الالتهابات (الأعراض المحتملة لقلَّة العَدِلات والتي تحدث جرّاء انخفاض عدد خلايا الدم البيضاء)، النزف التلقائي أو التكدّم (أعراض محتملة لقلّة الصفيحات التي يسببها انخفاض عدد الصفائح الدموية)&nbsp;</li><li>&nbsp; &nbsp; انخفاض أعداد ثلاثة أنواع من خلايا الدم - وهي خلايا الدم الحمراء، خلايا الدم البيضاء، والصفائح الدموية (قلة الكريات الشاملة)&nbsp;</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية أخرى </strong></p><p dir="RTL">تشمل الآثار الجانبية المحتملة الأخرى ما يلي. تحدث مع طبيبك، أو الصيدلي إذا أصبت بهذه الآثار الجانبية.</p><p dir="RTL"><em>شائعة جداً (قد تؤثر في أكثر من شخص واحد من كل 10 أشخاص): </em></p><ul dir="rtl"><li>&nbsp; &nbsp; ارتفاع مستوى الكوليسترول (فرط كوليسترول الدم)&nbsp;</li><li>&nbsp; &nbsp; صداع&nbsp;</li><li>&nbsp; &nbsp; ارتفاع ضغط الدم (فرط ضغط الدم)&nbsp;</li><li>&nbsp; &nbsp; شعور بالإعياء (غثيان)&nbsp;</li><li>&nbsp; &nbsp; نتائج فحص وظائف كبد غير طبيعية&nbsp;</li><li>&nbsp; &nbsp; زيادة مستوى الدم في إنزيمات من العضلات التي يمكن أن تشير إلى تلف العضلات و/أو تحلل العضلات (ارتفاع فوسفوكيناز كرياتين الدم)&nbsp;</li><li>&nbsp; &nbsp; زيادة مستوى الكرياتينين في الدم، وهي مادة يتم التخلص منها بشكل طبيعي عن طريق الكلى في البول، مما قد يعني أن كليتيك لا تعملان بشكل صحيح (زيادة الكرياتينين في الدم)</li></ul><p dir="RTL"><em>شائعة (قد تؤثر فيما يصل إلى شخص واحد من كل 10 أشخاص): </em></p><ul dir="rtl"><li>&nbsp; &nbsp; الحمى، الألم، الاحمرار، و/أو صعوبة التنفس (الأعراض المحتملة للإصابة بعدوى فيروس بي كيه)</li><li>&nbsp; &nbsp; زيادة في الوزن&nbsp;</li><li>&nbsp; &nbsp; إمساك</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">يحفظ عند درجة حرارة أقل من 30&deg; مئوية.</p><p dir="RTL">يحفظ داخل العبوة الأصلية.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية بعد &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت أي علامات تلف واضحة عليه.</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه الإجراءات ستساعد في الحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي فوسفات الروكسوليتينيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي كل<strong> </strong>قرص من سيليزون 5 ملغم أقراص على 6,6 ملغم فوسفات الروكسوليتينيب يكافئ 5 ملغم روكسوليتينيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي كل<strong> </strong>قرص من سيليزون 10 ملغم أقراص على 13.2 ملغم فوسفات الروكسوليتينيب يكافئ 10 ملغم روكسوليتينيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي كل<strong> </strong>قرص من سيليزون 15 ملغم أقراص على 19,8 ملغم فوسفات الروكسوليتينيب يكافئ 15 ملغم روكسوليتينيب. &nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي كل<strong> </strong>قرص من سيليزون 20 ملغم أقراص على 26.4 ملغم فوسفات الروكسوليتينيب يكافئ 20 ملغم روكسوليتينيب. &nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي كل<strong> </strong>قرص من سيليزون 25 ملغم أقراص على 33 ملغم فوسفات الروكسوليتينيب يكافئ 25 ملغم روكسوليتينيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">المواد الأخرى المستخدمة في التركيبة التصنيعية هي لاكتوز، سيلليلوز بلوري مكروي، هيدروكسي بروبيل السيلليلوز، بوڤيدون، جليكولات نشا الصوديوم، ثاني أكسيد السيليكون الغروي وستيرات المغننسيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيليزون 5 ملغم أقراص هي أقراص دائرية الشكل لونها أبيض مائل إلى الأبيض المصفر، منقوش عليها &quot;R4&quot; على أحد جانبيها في أشرطة من الألمنيوم-الألمنيوم. &nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيليزون 10 ملغم أقراص هي أقراص دائرية الشكل لونها أبيض مائل إلى الأبيض المصفر، منقوش عليها &quot;R3&quot; على أحد جانبيها في أشرطة من الألمنيوم-الألمنيوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيليزون 15 ملغم أقراص هي أقراص بيضاوية الشكل لونها أبيض مائل إلى الأبيض المصفر، منقوش عليها &quot;R2&quot; على أحد جانبيها في أشرطة من الألمنيوم-الألمنيوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيليزون 20 ملغم أقراص هي أقراص معدلة كبسولية الشكل لونها أبيض مائل إلى الأبيض المصفر، منقوش عليها &quot;R1&quot; على أحد جانبيها في أشرطة من الألمنيوم-الألمنيوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيليزون 25 ملغم أقراص هي أقراص بيضاوية الشكل لونها أبيض مائل إلى الأبيض المصفر، منقوش عليها &quot;R5&quot; على أحد جانبيها في أشرطة من الألمنيوم-الألمنيوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أحجام العبوات:</p><ul dir="rtl"><li>&nbsp; &nbsp; سيليزون 5 ملغم، 10 ملغم، 15 ملغم و20 ملغم أقراص: 56 قرص.</li><li>&nbsp; &nbsp; سيليزون 25 ملغم أقراص: 60 قرص.</li></ul>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>اسم وعنوان مالك رخصة التسويق ومحرر التشغيلة</strong></p><p dir="RTL">شركة الجزيرة للصناعات الدوائية<br />طريق الخرج<br />صندوق بريد 106229<br />الرياض 11666، المملكة العربية السعودية<br />هاتف: 8107023 (11-966) +، 2142472 (11-966) +<br />فاكس: 2078170 (11-966) +<br />البريد الإلكتروني: SAPV@hikma.com</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة المصنعة للمستحضر النهائي</strong></p><p dir="RTL">الشركة العربية لصناعة الأدوية المساهمة الخاصة</p><p dir="RTL">سحاب<br />المدينة الصناعية</p><p dir="RTL">صندوق بريد 41</p><p dir="RTL">عمان 11512، الأردن</p><p dir="RTL">هاتف: 4023916(6-962) +</p><p dir="RTL">فاكس: 4023917 (6-962) +</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">تحدث إلى الطبيب، الصيدلي، أو الممرض إذا عانيت من أية آثار جانبية. وذلك يشمل أي آثار جانبية لم يتم ذكرها في هذه النشرة. كما أنه يمكنك الإبلاغ عن هذه الآثار مباشرةً (انظر التفاصيل المذكورة أدناه). من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة بتوفير معلومات مهمة عن سلامة الدواء.</p><ul dir="rtl"><li>&nbsp; &nbsp; المملكة العربية السعودية</li></ul><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><p dir="RTL">مركز الاتصال الموحد: 19999</p><p dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني: &nbsp;https://ade.sfda.gov.sa</p><ul dir="rtl"><li>&nbsp; &nbsp; دول الخليج العربي الأخرى</li></ul><p dir="RTL">الرجاء الاتصال بالجهات الوطنية في كل دولة.</p><ul dir="rtl"><li>&nbsp; &nbsp; الإمارات العربية المتحدة</li></ul><p dir="RTL">قسم اليقظة الدوائية والجهاز الطبي</p><p dir="RTL">صندوق بريد: 1853</p><p dir="RTL">هاتف: 80011111</p><p dir="RTL">البريد الإلكتروني: pv@mohap.gov.ae</p><p dir="RTL">إدارة الدواء</p><p dir="RTL">وزارة الصحة ووقاية المجتمع</p><p dir="RTL">دبي</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 2022/11؛ رقم النسخة Un1.0. 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Celezon 10 mg Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 13.2 mg ruxolitinib phosphate equivalent to 10 mg ruxolitinib.  

Excipients with known effect: Lactose and sodium. 

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablets. 

White to off-white round-shaped tablets, embossed with "R3" on one side. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Myelofibrosis (MF)</strong></p><p>Celezon is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.</p><p>&nbsp;</p><p><strong>Polycythaemia vera (PV)</strong></p><p>Celezon is indicated for the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.</p><p>&nbsp;</p><p><strong>Graft versus host disease (GvHD)</strong></p><p>Celezon is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease who have inadequate response to corticosteroids.</p><p>&nbsp;</p><p>Celezon is indicated for the treatment of patients aged 12 years and older with chronic graft versus host disease who have inadequate response to corticosteroids. (see section 5.1).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Celezon treatment should only be initiated by a physician experienced in the administration of anti-cancer medicinal products.</p><p>A complete blood cell count, including a white blood cell count differential, must be performed before initiating therapy with Celezon.</p><p>&nbsp;</p><p>Complete blood count, including a white blood cell count differential, should be monitored every 2-4 weeks until Celezon doses are stabilised, and then as clinically indicated (see section 4.4).</p><p><strong>&nbsp;</strong></p><p><strong>Posology</strong></p><p><u>Starting dose </u></p><p>&nbsp;</p><p>The recommended starting dose of Celezon in myelofibrosis (MF) is based on platelet counts (see Table 1):</p><p>&nbsp;</p><p><strong>Table 1 Starting doses in myelofibrosis</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Platelet count</strong></p></td><td style="vertical-align:top"><p><strong>Starting dose</strong></p></td></tr><tr><td style="vertical-align:top"><p>Greater than 200,000/mm<sup>3</sup></p></td><td style="vertical-align:top"><p>20 mg orally twice daily</p></td></tr><tr><td style="vertical-align:top"><p>100,000 to 200,000/mm<sup>3</sup></p></td><td style="vertical-align:top"><p>15 mg orally twice daily</p></td></tr><tr><td style="vertical-align:top"><p>75,000 to less than 100,000/mm<sup>3</sup></p></td><td style="vertical-align:top"><p>10 mg orally twice daily</p></td></tr><tr><td style="vertical-align:top"><p>50,000 to less than 75,000/mm<sup>3</sup></p></td><td style="vertical-align:top"><p>5 mg orally twice daily</p></td></tr></tbody></table><p>&nbsp;</p><p>The recommended starting dose of Celezon in polycythaemia vera (PV) and acute and chronic graft versus host disease (GvHD) is 10 mg given orally twice daily.</p><p>&nbsp;</p><p><u>Dose modifications</u></p><p>Doses may be titrated based on efficacy and safety.</p><p>&nbsp;</p><p><em>Myelofibrosis and polycythaemia vera</em></p><p>If efficacy is considered insufficient and blood counts are adequate, doses may be increased by a maximum of 5 mg twice daily, up to the maximum dose of 25 mg twice daily.</p><p>&nbsp;</p><p>The starting dose should not be increased within the first four weeks of treatment and thereafter no more frequently than at 2-week intervals.</p><p>&nbsp;</p><p>Treatment should be discontinued for platelet counts less than 50,000/mm<sup>3</sup>&nbsp;or absolute neutrophil counts less than 500/mm<sup>3</sup>. In PV, treatment should also be interrupted when haemoglobin is below 8 g/dl. After recovery of blood counts above these levels, dosing may be re-started at 5 mg twice daily and gradually increased based on careful monitoring of complete blood cell count, including a white blood cell count differential.</p><p>&nbsp;</p><p>Dose reductions should be considered if the platelet count decreases during treatment as outlined in Table 2, with the goal of avoiding dose interruptions for thrombocytopenia.</p><p><strong>Table 2 Dosing recommendation for thrombocytopenia</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td>&nbsp;</td><td colspan="5"><p><strong>Dose at time of platelet decline</strong></p></td></tr><tr><td>&nbsp;</td><td><p>25 mg twice daily</p></td><td><p>20 mg twice daily</p></td><td><p>15 mg twice daily</p></td><td><p>10 mg twice daily</p></td><td><p>5 mg twice daily</p></td></tr><tr><td><p><strong>Platelet count</strong></p></td><td colspan="5"><p><strong>New dose</strong></p></td></tr><tr><td><p><strong>100,000 to &lt;125,000/mm<sup>3</sup></strong></p></td><td><p>20 mg twice daily</p></td><td><p>15 mg twice daily</p></td><td><p>No change</p></td><td><p>No change</p></td><td><p>No change</p></td></tr><tr><td><p><strong>75,000 to &lt;100,000/mm<sup>3</sup></strong></p></td><td><p>10 mg twice daily</p></td><td><p>10 mg twice daily</p></td><td><p>10 mg twice daily</p></td><td><p>No change</p></td><td><p>No change</p></td></tr><tr><td><p><strong>50,000 to &lt;75,000/mm<sup>3</sup></strong></p></td><td><p>5 mg twice daily</p></td><td><p>5 mg twice daily</p></td><td><p>5 mg twice daily</p></td><td><p>5 mg twice daily</p></td><td><p>No change</p></td></tr><tr><td><p><strong>Less than 50,000/mm<sup>3</sup></strong></p></td><td><p>Hold</p></td><td><p>Hold</p></td><td><p>Hold</p></td><td><p>Hold</p></td><td><p>Hold</p></td></tr></tbody></table><p>In PV, dose reductions should also be considered if haemoglobin decreases below 12 g/dl and is recommended if it decreases below 10 g/dl.</p><p>&nbsp;</p><p><em>Graft versus host disease</em></p><p>Dose reductions and temporary interruptions of treatment may be needed in GvHD-patients with thrombocytopenia, neutropenia, or elevated total bilirubin after standard supportive therapy including growth-factors, anti-infective therapies and transfusions. One dose level reduction step is recommended (10 mg twice daily to 5 mg twice daily or 5 mg twice daily to 5 mg once daily). In patients who are unable to tolerate Celezon at a dose of 5 mg once daily, treatment should be interrupted. Detailed dosing recommendations are provided in Table 3.</p><p>&nbsp;</p><p><strong>Table 3 Dosing recommendations for GvHD patients with thrombocytopenia, neutropenia, or elevated total bilirubin</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><p><strong>Laboratory parameter</strong></p></td><td><p><strong>Dosing recommendation</strong></p></td></tr><tr><td style="vertical-align:top"><p>Platelet count &lt;20,000/mm<sup>3</sup></p></td><td style="vertical-align:top"><p>Reduce Celezon by one dose level. If platelet count &ge;20,000/mm<sup>3</sup>&nbsp;within seven days, dose may be increased to initial dose level, otherwise maintain reduced dose.</p></td></tr><tr><td style="vertical-align:top"><p>Platelet count &lt;15,000/mm<sup>3</sup></p></td><td style="vertical-align:top"><p>Hold Celezon until platelet count &ge;20,000/mm<sup>3</sup>, then resume at one lower dose level.</p></td></tr><tr><td style="vertical-align:top"><p>Absolute neutrophil count (ANC) &ge;500/mm<sup>3</sup>&nbsp;to &lt;750/mm<sup>3</sup></p></td><td style="vertical-align:top"><p>Reduce Celezon by one dose level. Resume at initial dose level if ANC &gt;1,000/mm<sup>3</sup>.</p></td></tr><tr><td style="vertical-align:top"><p>Absolute neutrophil count &lt;500/mm<sup>3</sup></p></td><td style="vertical-align:top"><p>Hold Celezon until ANC &gt;500/mm<sup>3</sup>, then resume at one lower dose level. If ANC &gt;1,000/mm<sup>3</sup>, dosing may resume at initial dose level.</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Total bilirubin elevation, no liver GvHD</p></td><td style="vertical-align:top"><p>&gt;3.0 to 5.0 x ULN: Continue Celezon at one lower dose level until &le;3.0 x ULN.</p></td></tr><tr><td style="vertical-align:top"><p>&gt;5.0 to 10.0 x ULN: Hold Celezon up to 14 days until total bilirubin &le;3.0 x ULN. If total bilirubin &le;3.0 x ULN dosing may resume at current dose. If not &le;3.0 x ULN after 14 days, resume at one lower dose level.</p></td></tr><tr><td style="vertical-align:top"><p>&gt;10.0 x ULN: Hold Celezon until total bilirubin &le;3.0 x ULN, then resume at one lower dose level.</p></td></tr><tr><td style="vertical-align:top"><p>Total bilirubin elevation, liver GvHD</p></td><td style="vertical-align:top"><p>&gt;3.0 x ULN: Continue Celezon at one lower dose level until total bilirubin &le;3.0 x ULN.</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Dose adjustment with concomitant strong CYP3A4 inhibitors or fluconazole</u></p><p>When ruxolitinib is administered with strong CYP3A4 inhibitors in MF and PV patients or dual inhibitors of CYP2C9 and CYP3A4 enzymes (e.g. fluconazole) in MF, PV or GvHD patients, the unit dose of ruxolitinib should be reduced by approximately 50%, to be administered twice daily (see section 4.5). The concomitant use of ruxolitinib with fluconazole doses greater than 200 mg daily should be avoided.</p><p>&nbsp;</p><p>More frequent monitoring (e.g. twice a week) of haematology parameters and of clinical signs and symptoms of ruxolitinib-related adverse drug reactions is recommended while on strong CYP3A4 inhibitors or dual inhibitors of CYP2C9 and CYP3A4 enzymes.</p><p>&nbsp;</p><p><u>Special populations</u></p><p><em>Renal impairment</em></p><p>No specific dose adjustment is needed in patients with mild or moderate renal impairment.</p><p>In patients with severe renal impairment (creatinine clearance less than 30 ml/min) the recommended starting dose based on platelet count for MF patients should be reduced by approximately 50% to be administered twice daily. The recommended starting dose for PV and GvHD patients with severe renal impairment is 5 mg twice daily. Patients should be carefully monitored with regard to safety and efficacy during ruxolitinib treatment.</p><p>&nbsp;</p><p>There are limited data to determine the best dosing options for patients with end-stage renal disease (ESRD) on haemodialysis. Pharmacokinetic/pharmacodynamic simulations based on available data in this population suggest that the starting dose for MF patients with ESRD on haemodialysis is a single dose of 15-20 mg or two doses of 10 mg given 12 hours apart, to be administered post-dialysis and only on the day of haemodialysis. A single dose of 15 mg is recommended for MF patients with platelet count between 100,000/mm<sup>3</sup>&nbsp;and 200,000/mm<sup>3</sup>. A single dose of 20 mg or two doses of 10 mg given 12 hours apart is recommended for MF patients with platelet count of &gt;200,000/mm<sup>3</sup>. Subsequent doses (single administration or two doses of 10 mg given 12 hours apart) should be administered only on haemodialysis days following each dialysis session.</p><p>The recommended starting dose for PV patients with ESRD on haemodialysis is a single dose of 10 mg or two doses of 5 mg given 12 hours apart, to be administered post-dialysis and only on the day of haemodialysis. These dose recommendations are based on simulations and any dose modification in ESRD should be followed by careful monitoring of safety and efficacy in individual patients. No data is available for dosing patients who are undergoing peritoneal dialysis or continuous venovenous haemofiltration (see section 5.2).</p><p>&nbsp;</p><p>There are no data for GvHD patients with ESRD.</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>In MF patients with any hepatic impairment the recommended starting dose based on platelet count should be reduced by approximately 50% to be administered twice daily. Subsequent doses should be adjusted based on careful monitoring of safety and efficacy. The recommended starting dose is 5 mg twice daily for PV patients. Patients diagnosed with hepatic impairment while receiving ruxolitinib should have complete blood counts, including a white blood cell count differential, monitored at least every one to two weeks for the first 6 weeks after initiation of therapy with ruxolitinib and as clinically indicated thereafter once their liver function and blood counts have been stabilised. Ruxolitinib dose can be titrated to reduce the risk of cytopenia.</p><p>&nbsp;</p><p>In patients with mild, moderate or severe hepatic impairment not related to GvHD, the starting dose of ruxolitinib should be reduced by 50% (see section 5.2).</p><p>&nbsp;</p><p>In patients with GvHD liver involvement and an increase of total bilirubin to &gt;3 x ULN, blood counts should be monitored more frequently for toxicity and a dose reduction by one dose level may be considered.</p><p>&nbsp;</p><p><em>Elderly patients (&ge;65 years)</em></p><p>No additional dose adjustments are recommended for elderly patients.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy of ruxolitinib in children and adolescents aged up to 18 years with MF and PV have not been established. No data are available (see section 5.1).</p><p>&nbsp;</p><p>The Celezon dose in paediatric patients with GvHD aged 12 years and older is the same as in adults. The safety and efficacy of ruxolitinib have not been established in patients less than 12 years of age.</p><p>&nbsp;</p><p><u>Treatment discontinuation</u></p><p>Treatment of MF and PV may be continued as long as the benefit-risk remains positive. However the treatment should be discontinued after 6 months if there has been no reduction in spleen size or improvement in symptoms since initiation of therapy.</p><p>&nbsp;</p><p>It is recommended that, for patients who have demonstrated some degree of clinical improvement, ruxolitinib therapy be discontinued if they sustain an increase in their spleen length of 40% compared with baseline size (roughly equivalent to a 25% increase in spleen volume) and no longer have tangible improvement in disease-related symptoms.</p><p>&nbsp;</p><p>In GvHD, tapering of Celezon may be considered in patients with a response and after having discontinued corticosteroids. A 50% dose reduction of Celezon every two months is recommended. If signs or symptoms of GvHD reoccur during or after the taper of Celezon, re-escalation of treatment should be considered.</p><p>&nbsp;</p><p><strong>Method of administration</strong></p><p>Celezon is to be taken orally, with or without food.</p><p>&nbsp;</p><p>If a dose is missed, the patient should not take an additional dose, but should take the next usual prescribed dose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 

Pregnancy and lactation. 


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Myelosuppression</strong></p><p>Treatment with ruxolitinib can cause haematological adverse drug reactions, including thrombocytopenia, anaemia and neutropenia. A complete blood count, including a white blood cell count differential, must be performed before initiating therapy with Celezon Treatment should be discontinued in patients with platelet count less than 50,000/mm<sup>3</sup> or absoute neutrophil count less than 500/mm<sup>3</sup> (see section 4.2).</p><p>&nbsp;</p><p>It has been observed that MF patients with low platelet counts (&lt;200,000/mm<sup>3</sup>) at the start of therapy are more likely to develop thrombocytopenia during treatment.</p><p>&nbsp;</p><p>Thrombocytopenia is generally reversible and is usually managed by reducing the dose or temporarily withholding Celezon (see sections 4.2 and 4.8). However, platelet transfusions may be required as clinically indicated.</p><p>&nbsp;</p><p>Patients developing anaemia may require blood transfusions. Dose modifications or interruption for patients developing anaemia may also need to be considered.</p><p>&nbsp;</p><p>Patients with a haemoglobin level below 10.0 g/dl at the beginning of the treatment have a higher risk of developing a haemoglobin level below 8.0 g/dl during treatment compared to patients with a higher baseline haemoglobin level (79.3% versus 30.1%). More frequent monitoring of haematology parameters and of clinical signs and symptoms of ruxolitinib-related adverse drug reactions is recommended for patients with baseline haemoglobin below 10.0 g/dl.</p><p>Neutropenia (absolute neutrophil count &lt;500) was generally reversible and was managed by temporarily withholding ruxolitinib (see sections 4.2 and 4.8).</p><p>&nbsp;</p><p>Complete blood counts should be monitored as clinically indicated and dose adjusted as required (see sections 4.2 and 4.8).</p><p>&nbsp;</p><p><strong>Infections</strong></p><p>Serious bacterial, mycobacterial, fungal, viral and other opportunistic infections have occurred in patients treated with ruxolitinib. Patients should be assessed for the risk of developing serious infections. Physicians should carefully observe patients receiving ruxolitinib for signs and symptoms of infections and initiate appropriate treatment promptly. Treatment with ruxolitinib should not be started until active serious infections have resolved.</p><p>&nbsp;</p><p>Tuberculosis has been reported in patients receiving ruxolitinib. Before starting treatment, patients should be evaluated for active and inactive (&ldquo;latent&rdquo;) tuberculosis, as per local recommendations. This can include medical history, possible previous contact with tuberculosis, and/or appropriate screening such as lung x-ray, tuberculin test and/or interferon-gamma release assay, as applicable. Prescribers are reminded of the risk of false negative tuberculin skin test results, especially in patients who are severely ill or immunocompromised.</p><p>&nbsp;</p><p>Hepatitis B viral load (HBV-DNA titre) increases, with and without associated elevations in alanine aminotransferase and aspartate aminotransferase, have been reported in patients with chronic HBV infections taking ruxolitinib. It is recommended to screen for HBV prior to commencing treatment with ruxolitinib. Patients with chronic HBV infection should be treated and monitored according to clinical guidelines.</p><p>&nbsp;</p><p><strong>Herpes zoster</strong></p><p>Physicians should educate patients about early signs and symptoms of herpes zoster, advising that treatment should be sought as early as possible.</p><p>&nbsp;</p><p><strong>Progressive multifocal leukoencephalopathy</strong></p><p>Progressive multifocal leukoencephalopathy (PML) has been reported with ruxolitinib treatment. Physicians should be particularly alert to symptoms suggestive of PML that patients may not notice (e.g., cognitive, neurological or psychiatric symptoms or signs). Patients should be monitored for any of these new or worsening symptoms or signs, and if such symptoms/signs occur, referral to a neurologist and appropriate diagnostic measures for PML should be considered. If PML is suspected, further dosing must be suspended until PML has been excluded.</p><p>&nbsp;</p><p><strong>Non-melanoma skin cancer</strong></p><p>Non-melanoma skin cancers (NMSCs), including basal cell, squamous cell, and Merkel cell carcinoma, have been reported in patients treated with ruxolitinib. Most of the MF and PV patients had histories of extended treatment with hydroxyurea and prior NMSC or pre-malignant skin lesions. A causal relationship to ruxolitinib has not been established. Periodic skin examination is recommended for patients who are at increased risk for skin cancer.</p><p>&nbsp;</p><p><strong>Lipid abnormalities/elevations</strong></p><p>Treatment with ruxolitinib has been associated with increases in lipid parameters including total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides. Lipid monitoring and treatment of dyslipidaemia according to clinical guidelines is recommended.</p><p>&nbsp;</p><p><strong>Special populations</strong></p><p><em>Renal impairment</em></p><p>The starting dose of ruxolitinib should be reduced in patients with severe renal impairment. For patients with end-stage renal disease on haemodialysis the starting dose should be based on platelet counts for MF patients, while the recommended starting dose is a single dose of 10 mg for PV patients (see section 4.2). Subsequent doses (single dose of 20 mg or two doses of 10 mg given 12 hours apart in MF patients; single dose of 10 mg or two doses of 5 mg given 12 hours apart in PV patients) should be administered only on haemodialysis days following each dialysis session. Additional dose modifications should be made with careful monitoring of safety and efficacy (see sections 4.2 and 5.2).</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>The starting dose of ruxolitinib should be reduced by approximately 50% in MF and PV patients with hepatic impairment. Further dose modifications should be based on the safety and efficacy of the medicinal product. In GvHD patients with hepatic impairment not related to GvHD, the starting dose of ruxolitinib should be reduced by approximately 50% (see sections 4.2 and 5.2).</p><p>&nbsp;</p><p><strong>Interactions</strong></p><p>If ruxolitinib is to be co-administered with strong CYP3A4 inhibitors in MF and PV patients or dual inhibitors of CYP3A4 and CYP2C9 enzymes (e.g. fluconazole) in MF, PV and GvHD patients, the unit dose of ruxolitinib should be reduced by approximately 50%, to be administered twice daily (for monitoring frequency see sections 4.2 and 4.5).</p><p>The concomitant use of cytoreductive therapies with ruxolitinib was associated with manageable cytopenias (see section 4.2 for dose modifications during cytopenias).</p><p>&nbsp;</p><p><strong>Withdrawal effects</strong></p><p>Following interruption or discontinuation of ruxolitinib, symptoms of MF may return over a period of approximately one week. There have been cases of patients discontinuing ruxolitinib who experienced severe adverse events, particularly in the presence of acute intercurrent illness. It has not been established whether abrupt discontinuation of ruxolitinib contributed to these events. Unless abrupt discontinuation is required, gradual tapering of the dose of ruxolitinib may be considered, although the utility of the tapering is unproven.</p><p>&nbsp;</p><p><strong>Celezon </strong><strong>contains lactose and sodium</strong></p><p>Celezon contains lactose (milk sugar). Each tablet contains 142.4 mg lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p><p>&nbsp;</p><p>Celezon contains sodium. Each tablet contains 0.49 mg sodium. This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Interaction studies have only been performed in adults.</p><p>&nbsp;</p><p>Ruxolitinib is eliminated through metabolism catalysed by CYP3A4 and CYP2C9. Thus, medicinal products inhibiting these enzymes can give rise to increased ruxolitinib exposure.</p><p>&nbsp;</p><p><strong>Interactions resulting in dose reduction of ruxolitinib</strong></p><p><u>CYP3A4 inhibitors</u></p><p>Strong CYP3A4 inhibitors (such as, but not limited to, boceprevir, clarithromycin, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, ritonavir, mibefradil, nefazodone, nelfinavir, posaconazole, saquinavir, telaprevir, telithromycin, voriconazole).</p><p>&nbsp;</p><p>In healthy subjects co-administration of ruxolitinib (10 mg single dose) with a strong CYP3A4 inhibitor, ketoconazole, resulted in ruxolitinib C<sub>max</sub> and AUC that were higher by 33% and 91%, respectively, than with ruxolitinib alone. The half-life was prolonged from 3.7 to 6.0 hours with concurrent ketoconazole administration.</p><p>&nbsp;</p><p>When administering ruxolitinib with strong CYP3A4 inhibitors the unit dose of ruxolitinib should be reduced by approximately 50%, to be administered twice daily, except in GvHD patients. The effect of strong CYP3A4 inhibitors in patients with GvHD was not found to have a significant impact on any parameter in the population pharmacokinetic model.</p><p>&nbsp;</p><p>Patients should be closely monitored (e.g. twice weekly) for cytopenias and dose titrated based on safety and efficacy (see section 4.2).</p><p><em>Dual CYP2C9 and CYP3A4 inhibitors</em></p><p>In healthy subjects co-administration of ruxolitinib (10 mg single dose) with a dual CYP2C9 and CYP3A4 inhibitor, fluconazole, resulted in ruxolitinib C<sub>max</sub> and AUC that were higher by 47% and 232%, respectively, than with ruxolitinib alone.</p><p>&nbsp;</p><p>50% dose reduction should be considered when using medicinal products which are dual inhibitors of CYP2C9 and CYP3A4 enzymes (e.g. fluconazole). Avoid the concomitant use of ruxolitinib with fluconazole doses greater than 200 mg daily.</p><p>&nbsp;</p><p><strong>Enzyme inducers</strong></p><p><u>CYP3A4 inducers (such as, but not limited to, avasimibe, carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin (rifampicin), St.John&#39;s wort (Hypericum perforatum))</u></p><p>Patients should be closely monitored and the dose titrated based on safety and efficacy (see section 4.2).</p><p>&nbsp;</p><p>In healthy subjects given ruxolitinib (50 mg single dose) following the potent CYP3A4 inducer rifampicin (600 mg daily dose for 10 days), ruxolitinib AUC was 70% lower than after administration of ruxolitinib alone. The exposure of ruxolitinib active metabolites was unchanged. Overall, the ruxolitinib pharmacodynamic activity was similar, suggesting the CYP3A4 induction resulted in minimal effect on the pharmacodynamics. However, this could be related to the high ruxolitinib dose resulting in pharmacodynamic effects near E<sub>max</sub>. It is possible that in the individual patient, an increase of the ruxolitinib dose is needed when initiating treatment with a strong enzyme inducer.</p><p>&nbsp;</p><p><strong>Other interactions to be considered affecting ruxolitinib</strong></p><p><u>Mild or moderate CYP3A4 inhibitors (such as, but not limited to, ciprofloxacin, erythromycin, amprenavir, atazanavir, diltiazem, cimetidine)</u></p><p>In healthy subjects co-administration of ruxolitinib (10 mg single dose) with erythromycin 500 mg twice daily for four days resulted in ruxolitinib C<sub>max</sub> and AUC that were higher by 8% and 27%, respectively, than with ruxolitinib alone.</p><p>&nbsp;</p><p>No dose adjustment is recommended when ruxolitinib is co-administered with mild or moderate CYP3A4 inhibitors (e.g. erythromycin). However, patients should be closely monitored for cytopenias when initiating therapy with a moderate CYP3A4 inhibitor.</p><p>&nbsp;</p><p><strong>Effects of ruxolitinib on other medicinal products</strong></p><p><u>Substances transported by P-glycoprotein or other transporters</u></p><p>Ruxolitinib may inhibit P-glycoprotein and breast cancer resistance protein (BCRP) in the intestine. This may result in increased sytemic exposure of substrates of these transporters, such as dabigatran etexilate, ciclosporin, rosuvastatin and potentially digoxin. Therapeutic drug monitoring (TDM) or clinical monitoring of the affected substance is advised.</p><p>It is possible that the potential inhibition of P-gp and BCRP in the intestine can be minimised if the time between administrations is kept apart as long as possible.</p><p>&nbsp;</p><p>A study in healthy subjects indicated that ruxolitinib did not inhibit the metabolism of the oral CYP3A4 substrate midazolam. Therefore, no increase in exposure of CYP3A4 substrates is anticipated when combining them with ruxolitinib. Another study in healthy subjects indicated that ruxolitinib does not affect the pharmacokinetics of an oral contraceptive containing ethinylestradiol and levonorgestrel. Therefore, it is not anticipated that the contraceptive efficacy of this combination will be compromised by co-administration of ruxolitinib.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong></p><p>There are no data from the use of ruxolitinib in pregnant women.</p><p>&nbsp;</p><p>Animal studies have shown that ruxolitinib is embryotoxic and foetotoxic. Teratogenicity was not observed in rats or rabbits. However, the exposure margins compared to the highest clinical dose were low and the results are therefore of limited relevance for humans (see section 5.3). The potential risk for humans is unknown. As a precautionary measure, the use of Celezon during pregnancy is contraindicated (see section 4.3).</p><p>&nbsp;</p><p><strong>Women of childbearing potential/Contraception</strong></p><p>Women of child-bearing potential should use effective contraception during the treatment with Celezon. In case pregnancy should occur during treatment with Celezon, a risk/benefit evaluation must be carried out on an individual basis with careful counselling regarding potential risks to the foetus (see section 5.3).</p><p>&nbsp;</p><p><strong>Breast-feeding</strong></p><p>Celezon must not be used during breast-feeding (see section 4.3) and breast-feeding should therefore be discontinued when treatment is started. It is unknown whether ruxolitinib and/or its metabolites are excreted in human milk. A risk to the breast-fed child cannot be excluded. Available pharmacodynamic/toxicological data in animals have shown excretion of ruxolitinib and its metabolites in milk (see section 5.3).</p><p>&nbsp;</p><p><strong>Fertility</strong></p><p>There are no human data on the effect of ruxolitinib on fertility. In animal studies, no effect on fertility was observed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ruxolitinib has no or negligible sedating effect. However, patients who experience dizziness after the intake of Celezon should refrain from driving or using machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Summary of the safety profile</strong></p><p><u>Myelofibrosis</u></p><p>The most frequently reported adverse drug reactions were thrombocytopenia and anaemia.</p><p>Haematological adverse drug reactions (any Common Terminology Criteria for Adverse Events [CTCAE] grade) included anaemia (83.8%), thrombocytopenia (80.5%) and neutropenia (20.8%).</p><p>&nbsp;</p><p>Anaemia, thrombocytopenia and neutropenia are dose-related effects.</p><p>&nbsp;</p><p>The three most frequent non-haematological adverse drug reactions were bruising (33.3%), other bleeding (including epistaxis, post-procedural haemorrhage and haematuria) (24.3%) and dizziness (21.9%).</p><p>&nbsp;</p><p>The three most frequent non-haematological laboratory abnormalities identified as adverse reactions were increased alanine aminotransferase (40.7%), increased aspartate aminotransferase (31.5%) and hypertriglyceridaemia (25.2%). In phase 3 clinical studies in MF, neither CTCAE grade 3 or 4 hypertriglyceridaemia or increased aspartate aminotransferase, nor CTCAE grade 4 increased alanine aminotransferase or hypercholesterolaemia were observed.</p><p>&nbsp;</p><p>Discontinuation due to adverse events, regardless of causality, was observed in 30.0% of patients.</p><p>&nbsp;</p><p><u>Polycythaemia vera</u></p><p>The most frequently reported adverse drug reactions were anaemia and increased alanine aminotransferase.</p><p>&nbsp;</p><p>Haematological adverse reactions (any CTCAE grade) included anaemia (61.8%), thrombocytopenia (25.0%) and neutropenia (5.3%). Anaemia and thrombocytopenia CTCAE grade 3 or 4 were reported in 2.9% and 2.6% of the patients, respectively.</p><p>&nbsp;</p><p>The three most frequent non-haematological adverse reactions were weight gain (20.3%), dizziness (19.4%) and headache (17.9%).</p><p>&nbsp;</p><p>The three most frequent non-haematological laboratory abnormalities (any CTCAE grade) identified as adverse reactions were increased alanine aminotransferase (45.3%), increased aspartate aminotransferase (42.6%), and hypercholesterolaemia (34.7%). No CTCAE grade 4 increased alanine aminotransferase or hypercholesterolaemia, and one CTCAE grade 4 increased aspartate aminotransferase were observed.</p><p>&nbsp;</p><p>Discontinuation due to adverse events, regardless of causality, was observed in 19.4% of patients.</p><p>&nbsp;</p><p><u>Acute GvHD</u></p><p><em>REACH 1</em></p><p>The most frequently reported overall adverse drug reactions were anaemia, thrombocytopenia, and neutropenia.</p><p>&nbsp;</p><p>Hematological laboratory abnormalities identified as adverse drug reactions included anaemia (87.1%), thrombocytopenia (84.1%) and neutropenia (65.2%). Grade 3 anaemia was reported in 51.6% of patients (Grade 4 not applicable per CTCAE v4.03). Grade 3 and 4 thrombocytopenia were reported in 24.0% and 49.2% of patients, respectively.</p><p>&nbsp;</p><p>The most frequent non-hematological adverse drug reactions were nausea (32.4%), sepsis (22.5%) and hypertension (22.5%).</p><p>&nbsp;</p><p>The most frequent non-hematological laboratory abnormalities identified as adverse drug reactions were increased ALT (50.7%), increased AST (50.7%). The majority were of grade 1 and 2.</p><p>&nbsp;</p><p>Discontinuation due to adverse events, regardless of causality, was observed in 32.4% of patients.</p><p>&nbsp;</p><p><em>REACH 2</em></p><p>The most frequently reported overall adverse drug reactions were thrombocytopenia, anaemia and neutropenia.</p><p>&nbsp;</p><p>Haematological laboratory abnormalities identified as adverse drug reactions included thrombocytopenia (85.2%), anaemia (75.0%) and neutropenia (65.1%). Grade 3 anaemia was reported in 47.7% of patients (grade 4 not applicable per CTCAE v4.03). Grade 3 and 4 thrombocytopenia were reported in 31.3% and 47.7% of patients, respectively.</p><p>&nbsp;</p><p>The three most frequent non-haematological adverse drug reactions were cytomegalovirus (CMV) infection (32.3%), sepsis (25.4%) and urinary tract infections (17.9%).</p><p>&nbsp;</p><p>The three most frequent non-haematological laboratory abnormalities identified as adverse drug reactions were increased alanine aminotransferase (54.9%), increased aspartate aminotransferase (52.3%) and hypercholesterolaemia (49.2%). The majority were of grade 1 and 2.</p><p>&nbsp;</p><p>Discontinuation due to adverse events, regardless of causality, was observed in 29.4% of patients.</p><p>&nbsp;</p><p><u>Chronic GvHD</u></p><p>The most frequently reported overall adverse drug reactions were anaemia, hypercholesterolemia and increased aspartate aminotransferase.</p><p>&nbsp;</p><p>Haematological laboratory abnormalities identified as adverse drug reactions included anaemia (68.6%), thrombocytopenia (34.4%) and neutropenia (36.2%). Grade 3 anaemia was reported in 14.8% of patients (grade 4 not applicable per CTCAE v4.03). Grade 3 and 4 neutropenia were reported in 9.5% and 6.7% of patients, respectively.</p><p>&nbsp;</p><p>The three most frequent non-haematological adverse drug reactions were hypertension (15.0%), headache (10.2%) and urinary tract infections (9.3%).</p><p>&nbsp;</p><p>The three most frequent non-haematological laboratory abnormalities identified as adverse drug reactions were hypercholesterolaemia (52.3%), increased aspartate aminotransferase (52.2%) and increased alanine aminotransferase (43.1%). The majority were grade 1 and 2.</p><p>&nbsp;</p><p>Discontinuation due to adverse events, regardless of causality, was observed in 18.1% of patients.</p><p>&nbsp;</p><p><strong>Paediatric patients:</strong></p><p>A total of 20 patients aged 12 to &lt;18 years with GvHD were analysed for safety: 9 patients (5 in the ruxolitinib arm and 4 in the best available treatment [BAT] arm) in the study REACH2 and 11 patients (4 in the ruxolitinib arm and 7 in the BAT arm) in the study REACH3. Based on the similar exposure observed in adolescents and adults, the safety of ruxolitinib at the recommended dose of 10 mg twice daily is similar in frequency and severity.</p><p>&nbsp;</p><p><strong>Tabulated list of adverse drug reactions from clinical studies</strong></p><p>The safety of ruxolitinib in MF patients was evaluated using the long-term follow-up data from two phase 3 studies (COMFORT-I and COMFORT-II) including data from patients initially randomised to ruxolitinib (n=301) and patients who received ruxolitinib after crossing over from control treatments (n=156). The median exposure upon which the adverse drug reaction frequency categories for MF patients are based was 30.5 months (range 0.3 to 68.1 months).</p><p>&nbsp;</p><p>The safety of ruxolitinib in PV patients was evaluated using the long-term follow-up data from two phase 3 studies (RESPONSE, RESPONSE 2) including data from patients initially randomised to ruxolitinib (n=184) and patients who received ruxolitinib after crossing over from control treatments (n=156). The median exposure upon which the adverse drug reaction frequency categories for PV patients are based was 41.7 months (range 0.03 to 59.7 months).</p><p>&nbsp;</p><p>The safety of ruxolitinib in acute GvHD patients was evaluated in the phase 2 study REACH1, including data from 71 patients treated with ruxolitinib, and the phase 3 study REACH2, including data from patients initially randomised to ruxolitinib (n=152) and patients who received ruxolitinib after crossing over from BAT (n=49). In REACH1, the median exposure upon which the adverse drug reaction frequency categories were based was 6.6 weeks (range 0.6 to 115.9 weeks). In REACH2, the median exposure was 8.9 weeks (range 0.3 to 66.1 weeks).</p><p>&nbsp;</p><p>The safety of ruxolitinib in chronic GvHD patients was evaluated in the phase 3 study REACH3, including data from patients initially randomised to ruxolitinib (n=165) and patients who received ruxolitinib after crossing over from BAT (n=61). The median exposure upon which the adverse drug reaction frequency categories were based was 41.4 weeks (range 0.7 to 127.3 weeks).</p><p>&nbsp;</p><p>See section 5.1 for details of dose administered in each study.</p><p>&nbsp;</p><p>In the clinical study programme the severity of adverse drug reactions was assessed based on the CTCAE, defining grade 1 mild, grade 2=moderate, grade 3=severe, grade 4=life-threatening or disabling, grade 5=death.</p><p>&nbsp;</p><p>Adverse drug reactions from clinical studies in MF and PV (Table 4) and in acute and chronic GvHD (Table 5) are listed by MedDRA system organ class. Within each system organ class, the adverse drug reactions are ranked by frequency, with the most frequent reactions first. In addition, the corresponding frequency category for each adverse drug reaction is based on the following convention: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000); not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p><strong>Table 4 Frequency category of adverse drug reactions reported in the phase 3 studies in MF and PV</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Adverse drug reaction</strong></p></td><td style="vertical-align:top"><p><strong>Frequency category for MF patients</strong></p></td><td style="vertical-align:top"><p><strong>Frequency category for PV patients</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td><p>Urinary tract infections<sup>d</sup></p></td><td><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td><p>Herpes zoster<sup>d</sup></p></td><td><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td><p>Pneumonia</p></td><td><p>Very common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td><p>Sepsis</p></td><td><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td><p>Tuberculosis</p></td><td><p>Uncommon</p></td><td style="vertical-align:top"><p>Not known<sup>e</sup></p></td></tr><tr><td><p>HBV reactivation</p></td><td><p>Not known<sup>e</sup></p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders<sup>a,d</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Anaemia<sup>a</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>CTCAE<sup>c</sup>&nbsp;grade 4</p><p>(&lt;6.5g/dl)</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>CTCAE<sup>c</sup>&nbsp;grade 3</p><p>(&lt;8.0 &ndash; 6.5g/dl)</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Any CTCAE<sup>c</sup>&nbsp;grade</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia<sup>a</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td><p>CTCAE<sup>c</sup>&nbsp;grade 4</p><p>(&lt;25,000/mm<sup>3</sup>)</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td><p>CTCAE<sup>c</sup>&nbsp;grade 3</p><p>(50,000 &ndash; 25,000/mm<sup>3</sup>)</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td><p>Any CTCAE<sup>c</sup>&nbsp;grade</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Neutropenia<sup>a</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td><p>CTCAE<sup>c</sup>&nbsp;grade 4</p><p>(&lt;500/mm<sup>3</sup>)</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td><p>CTCAE<sup>c</sup>&nbsp;grade 3</p><p>(&lt;1,000 &ndash; 500/mm<sup>3</sup>)</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td><p>Any CTCAE<sup>c</sup>&nbsp;grade</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Pancytopenia<sup>a,b</sup></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Bleeding (any bleeding including intracranial, and gastrointestinal bleeding, bruising and other bleeding)</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Bruising</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal bleeding</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Intracranial bleeding</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Other bleeding (including epistaxis, post-procedural haemorrhage and haematuria)</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Hypercholesterolaemia<sup>a</sup>&nbsp;any CTCAE<sup>c</sup>&nbsp;grade</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td><p>Hypertriglyceridaemia<sup>b</sup>&nbsp;any CTCAE<sup>c</sup>&nbsp;grade</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Weight gain</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td><p>Elevated lipase, any CTCAE<sup>c</sup>&nbsp;grade</p></td><td><p>Very common</p></td><td><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Flatulence</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Increased alanine aminotransferase<sup>a</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td><p>CTCAE<sup>c</sup>&nbsp;grade 3</p><p>(&gt; 5x &ndash; 20 x ULN)</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td><p>Any CTCAE<sup>c</sup>&nbsp;grade</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Increased aspartate aminotransferase<sup>a</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td><p>Any CTCAE<sup>c</sup>&nbsp;grade</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td><p>Vascular disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td><p>Hypertension</p></td><td><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a&nbsp;</sup>Frequency is based on new or worsened laboratory abnormalities compared to baseline.</p><p><sup>b&nbsp;</sup>Pancytopenia is defined as haemoglobin level &lt;100 g/l, platelet count &lt;100x10<sup>9</sup>/l, and neutrophil count &lt;1.5x10<sup>9</sup>/l (or low white blood cell count of grade 2 if neutrophil count is missing), simultaneously in the same lab assessment.</p><p><sup>c&nbsp;</sup>Common Terminology Criteria for Adverse Events (CTCAE) version 3.0; grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life-threatening.</p><p><sup>d&nbsp;</sup>These ADRs are discussed in the text.</p><p><sup>e&nbsp;</sup>ADR derived from post-marketing experience.</p></td></tr></tbody></table><p>&nbsp;</p><p>Upon discontinuation, MF patients may experience a return of MF symptoms such as fatigue, bone pain, fever, pruritus, night sweats, symptomatic splenomegaly and weight loss. In clinical studies in MF the total symptom score for MF symptoms gradually returned to baseline value within 7 days after dose discontinuation (see section 4.4).</p><p>&nbsp;</p><p><strong>Table 5 ADRs reported in the studies in GvHD</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td>&nbsp;</td><td colspan="3"><p><strong>Acute GvHD (REACH1)</strong></p><p><strong>(N=71)</strong></p></td><td colspan="3"><p><strong>Chronic GvHD (REACH3)</strong></p><p><strong>(N=226)</strong></p></td></tr><tr><td><p><strong>Adverse drug reaction</strong></p></td><td><p>Frequency category</p></td><td style="vertical-align:top"><p>All grades</p><p>(%)</p></td><td style="vertical-align:top"><p>CTCAE<sup>3</sup>&nbsp;Grade 3/4</p><p>(%)</p></td><td style="vertical-align:top"><p>Frequency category</p></td><td style="vertical-align:top"><p>All grades</p><p>(%)</p></td><td style="vertical-align:top"><p>CTCAE<sup>3</sup></p><p>Grade 3/4</p><p>(%)</p></td></tr><tr><td colspan="7"><p><strong>Infections and infestations</strong></p></td></tr><tr><td style="vertical-align:top"><p>CMV infections</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>19.7</p></td><td style="vertical-align:top"><p>8.5 / 0</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>- / -</p></td></tr><tr><td style="vertical-align:top"><p>Sepsis</p></td><td><p>Very common</p></td><td><p>22.5</p></td><td><p>4.2 / 16.9<sup>4</sup></p></td><td><p>-</p></td><td><p>-</p></td><td><p>- / -</p></td></tr><tr><td style="vertical-align:top"><p>Urinary tract infections</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>14.1</p></td><td style="vertical-align:top"><p>8.5 / 0</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>9.3</p></td><td style="vertical-align:top"><p>1.3 / 0</p></td></tr><tr><td style="vertical-align:top"><p>BK virus infections</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>- / -</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>4.9</p></td><td style="vertical-align:top"><p>0.4 / 0</p></td></tr><tr><td colspan="7"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia<sup>1</sup></p></td><td><p>Very common</p></td><td style="vertical-align:top"><p>84.1</p></td><td style="vertical-align:top"><p>24.0 / 49.2</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>34.4</p></td><td style="vertical-align:top"><p>5.9 / 10.7</p></td></tr><tr><td style="vertical-align:top"><p>Anaemia<sup>1</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>87.1</p></td><td style="vertical-align:top"><p>51.6 / NA</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>68.6</p></td><td style="vertical-align:top"><p>14.8 / NA</p></td></tr><tr><td style="vertical-align:top"><p>Neutropenia<sup>1</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>65.2</p></td><td style="vertical-align:top"><p>29.2 / 15.9</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>36.2</p></td><td style="vertical-align:top"><p>9.5 / 6.7</p></td></tr><tr><td style="vertical-align:top"><p>Pancytopenia<sup>1,2</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>23.9</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>- / -</p></td></tr><tr><td colspan="7"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hypercholesterolaemia<sup>1,5</sup></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>1.4</p></td><td style="vertical-align:top"><p>0 / 1.4</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>52.3</p></td><td style="vertical-align:top"><p>5.5 / 0.5</p></td></tr><tr><td style="vertical-align:top"><p>Weight gain</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>3.5</p></td><td style="vertical-align:top"><p>0 / 0</p></td></tr><tr><td colspan="7"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>21.1</p></td><td style="vertical-align:top"><p>4.2 / 0</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>10.2</p></td><td style="vertical-align:top"><p>1.3 / 0</p></td></tr><tr><td colspan="7"><p>Vascular disorders</p></td></tr><tr><td style="vertical-align:top"><p>Hypertension</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>22.5</p></td><td style="vertical-align:top"><p>14.1 / 0</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>15.0</p></td><td style="vertical-align:top"><p>5.3 / 0</p></td></tr><tr><td colspan="7"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Increased lipase<sup>1</sup></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>35.9</p></td><td style="vertical-align:top"><p>9.5 / 0.4</p></td></tr><tr><td style="vertical-align:top"><p>Increased amylase<sup>1</sup></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>32.4</p></td><td style="vertical-align:top"><p>4.2 / 2.7</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>32.4</p></td><td style="vertical-align:top"><p>5.6 / 0</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>- / -</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>6.6</p></td><td style="vertical-align:top"><p>0 / 0</p></td></tr><tr><td colspan="7"><p>Hepatobiliary disorders</p></td></tr><tr><td style="vertical-align:top"><p>Increased alanine aminotransferase<sup>1</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>50.7</p></td><td style="vertical-align:top"><p>9.8 / 0</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>43.1</p></td><td style="vertical-align:top"><p>4.7 / 0.9</p></td></tr><tr><td style="vertical-align:top"><p>Increased aspartate aminotransferase<sup>1</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>50.7</p></td><td style="vertical-align:top"><p>5.8 / 0</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>52.2</p></td><td style="vertical-align:top"><p>3.1 / 0.9</p></td></tr><tr><td colspan="7"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Increased blood creatine phosphokinase<sup>1</sup></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>31.1</p></td><td style="vertical-align:top"><p>1.0 / 1.4</p></td></tr><tr><td colspan="7"><p><strong>Renal and urinary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Increased blood creatinine<sup>1</sup></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>38.4</p></td><td style="vertical-align:top"><p>1.3 / 0</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p>NA = not applicable</p><p><sup>1</sup>&nbsp;Frequency is based on new or worsened laboratory abnormalities compared to baseline.</p><p><sup>2&nbsp;</sup>Pancytopenia is defined as haemoglobin level &lt;100 g/l, platelet count &lt;100 x 10<sup>9</sup>/l, and neutrophil count &lt;1.5 x 10<sup>9</sup>/l (or low white blood cell count of grade 2 if neutrophil count is missing), simultaneously in the same laboratory assessment.</p><p><sup>3&nbsp;</sup>CTCAE Version 4.03.</p><p><sup>4&nbsp;</sup>Grade 4 sepsis includes 16 (8%) grade 4 events and 20 (10%) grade 5 events.</p><p><sup>5</sup>&nbsp;Frequency for REACH1 is based on AE data rather than laboratory values, because cholesterol laboratory parameter was not collected in the study. Frequency for REACH3 is based on laboratory values.</p></td></tr></tbody></table><p>&nbsp;</p><p>The safety of ruxolitinib in acute GvHD patients was also evaluated in the phase 3 study REACH2, including data from patients initially randomized to ruxolitinib (n=152) and patients who received ruxolitinib after crossing over from control treatment (n=49).</p><p>&nbsp;</p><p><strong>Table 6 ADRs reported in the supportive acute GvHD study</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td>&nbsp;</td><td colspan="3"><p><strong>Acute GvHD (REACH2)</strong></p><p><strong>(N=201)</strong></p></td></tr><tr><td><p><strong>Adverse drug reaction</strong></p></td><td><p>Frequency category</p></td><td style="vertical-align:top"><p>All grades</p><p>(%)</p></td><td style="vertical-align:top"><p>CTCAE<sup>3</sup>&nbsp;Grade 3/4</p><p>(%)</p></td></tr><tr><td colspan="4"><p><strong>Infections and infestations</strong></p></td></tr><tr><td style="vertical-align:top"><p>CMV infections</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>32.3</p></td><td style="vertical-align:top"><p>10.9 / 0.5</p></td></tr><tr><td style="vertical-align:top"><p>Sepsis</p></td><td><p>Very common</p></td><td><p>25.4</p></td><td><p>4.0 / 17.9<sup>4</sup></p></td></tr><tr><td style="vertical-align:top"><p>Urinary tract infections</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>17.9</p></td><td style="vertical-align:top"><p>6.0 / 0.5</p></td></tr><tr><td colspan="4"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia<sup>1</sup></p></td><td><p>Very common</p></td><td><p>85.2</p></td><td style="vertical-align:top"><p>31.3 / 47.7</p></td></tr><tr><td style="vertical-align:top"><p>Anaemia<sup>1</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>75.0</p></td><td style="vertical-align:top"><p>47.7 / NA</p></td></tr><tr><td style="vertical-align:top"><p>Neutropenia<sup>1</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>65.1</p></td><td style="vertical-align:top"><p>17.9 / 20.6</p></td></tr><tr><td style="vertical-align:top"><p>Pancytopenia<sup>1,2</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>32.8</p></td><td style="vertical-align:top"><p>NA</p></td></tr><tr><td colspan="4"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hypercholesterolaemia<sup>1</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>49.2</p></td><td style="vertical-align:top"><p>3.3 / 5.9</p></td></tr><tr><td colspan="4"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>8.5</p></td><td style="vertical-align:top"><p>0.5 / 0</p></td></tr><tr><td colspan="4"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hypertension</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>13.4</p></td><td style="vertical-align:top"><p>5.5 / 0</p></td></tr><tr><td colspan="4"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>16.4</p></td><td style="vertical-align:top"><p>0.5 / 0</p></td></tr><tr><td colspan="4"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Increased alanine aminotransferase<sup>1</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>54.9</p></td><td style="vertical-align:top"><p>17.6 / 1.5</p></td></tr><tr><td style="vertical-align:top"><p>Increased aspartate aminotransferaseAST<sup>1</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>52.3</p></td><td style="vertical-align:top"><p>7.8 / 0</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>NA = not applicable</p><p><sup>1</sup>&nbsp;Frequency is based on new or worsened laboratory abnormalities compared to baseline.</p><p><sup>2&nbsp;</sup>Pancytopenia is defined as haemoglobin level &lt;100 g/l, platelet count &lt;100 x 10<sup>9</sup>/l, and neutrophil count &lt;1.5 x 10<sup>9</sup>/l (or low white blood cell count of grade 2 if neutrophil count is missing), simultaneously in the same laboratory assessment.</p><p><sup>3&nbsp;</sup>CTCAE Version 4.03.</p><p><sup>4&nbsp;</sup>Grade 4 sepsis includes 16 (8%) grade 4 events and 20 (10%) grade 5 events.</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Description of selected adverse drug reactions</strong></p><p><u>Anaemia</u></p><p>In phase 3 clinical studies in MF, median time to onset of first CTCAE grade 2 or higher anaemia was 1.5 months. One patient (0.3%) discontinued treatment because of anaemia.</p><p>&nbsp;</p><p>In patients receiving ruxolitinib mean decreases in haemoglobin reached a nadir of approximately 10 g/litre below baseline after 8 to 12 weeks of therapy and then gradually recovered to reach a new steady state that was approximately 5 g/litre below baseline. This pattern was observed in patients regardless of whether they had received transfusion during therapy.</p><p>&nbsp;</p><p>In the randomised, placebo-controlled study COMFORT-I 60.6% of ruxolitinib-treated MF patients and 37.7% of placebo-treated MF patients received red blood cell transfusions during randomised treatment. In the COMFORT-II study the rate of packed red blood cell transfusions was 53.4% in the ruxolitinib arm and 41.1% in the best available therapy arm.</p><p>&nbsp;</p><p>In the randomised period of the pivotal studies, anaemia was less frequent in PV patients than in MF patients (40.8% versus 82.4%). In the PV population, the CTCAE grade 3 and 4 events were reported in 2.7%, while in the MF patients the frequency was 42.56%.</p><p>&nbsp;</p><p>In the acute GvHD studies, anaemia CTCAE Grade 3 was reported in 51.6% (REACH 1) and 47.7% (REACH2) of patients.</p><p>&nbsp;</p><p>In the phase 3 chronic GvHD study, anaemia CTCAE Grade 3 was reported in 47.7% and 14.8% of patients, respectively.</p><p>&nbsp;</p><p><u>Thrombocytopenia</u></p><p>In the phase 3 clinical studies in MF, in patients who developed grade 3 or 4 thrombocytopenia, the median time to onset was approximately 8 weeks. Thrombocytopenia was generally reversible with dose reduction or dose interruption. The median time to recovery of platelet counts above 50,000/mm<sup>3</sup>&nbsp;was 14 days. During the randomised period, platelet transfusions were administered to 4.7% of patients receiving ruxolitinib and to 4.0% of patients receiving control regimens. Discontinuation of treatment because of thrombocytopenia occurred in 0.7% of patients receiving ruxolitinib and 0.9% of patients receiving control regimens. Patients with a platelet count of 100,000/mm<sup>3</sup>&nbsp;to 200,000/mm<sup>3</sup>&nbsp;before starting ruxolitinib had a higher frequency of grade 3 or 4 thrombocytopenia compared to patients with platelet count &gt;200,000/mm<sup>3</sup>&nbsp;(64.2% versus 38.5%).</p><p>&nbsp;</p><p>In the randomised period of the pivotal studies, the rate of patients experiencing thrombocytopenia was lower in PV (16.8%) patients compared to MF (69.8%) patients. The frequency of severe (i.e. CTCAE grade 3 and 4) thrombocytopenia was lower in PV (2.7%) than in MF (11.6%) patients.</p><p>&nbsp;</p><p>In the acute GvHD study (REACH1) Grade 3 and 4 thrombocytopenia was observed in 24.0% and 49.2% of patients, respectively. In the acute GvHD study (REACH2) Grade 3 and 4 thrombocytopenia was observed in 31.3% and 47.7% of patients, respectively.</p><p>In the phase 3 chronic GvHD study, grade 3 and 4 thrombocytopenia was lower (5.9% and 10.7%) than in acute GvHD.</p><p>&nbsp;</p><p><u>Neutropenia</u></p><p>In the phase 3 clinical studies in MF, in patients who developed grade 3 or 4 neutropenia, the median time to onset was 12 weeks. During the randomised period, dose holding or reductions due to neutropenia were reported in 1.0% of patients, and 0.3% of patients discontinued treatment because of neutropenia.</p><p>&nbsp;</p><p>In the randomised period of the phase 3 studies in PV patients, neutropenia was reported in 1.6% of patients exposed to ruxolitinib compared to 7% in reference treatments. In the ruxolitinib arm one patient developed CTCAE grade 4 neutropenia. An extended follow-up of patients treated with ruxolitinib showed 2 patients reporting CTCAE grade 4 neutropenia.</p><p>&nbsp;</p><p>In the acute GvHD study (REACH1), Grade 3 and 4 neutropenia was observed in 29.2% and 15.9% of patients, respectively. In the acute GvHD study (REACH2), Grade 3 and 4 neutropenia was observed in 17.9% and 20.6% of patients, respectively.</p><p>&nbsp;</p><p>In the phase 3 chronic GvHD study grade 3 and 4 neutropenia was lower (9.5% and 6.7%) than in acute GvHD.</p><p>&nbsp;</p><p><u>Bleeding</u></p><p>In the phase 3 pivotal studies in MF bleeding events (including intracranial and gastrointestinal, bruising and other bleeding events) were reported in 32.6% of patients exposed to ruxolitinib and 23.2% of patients exposed to the reference treatments (placebo or best available therapy). The frequency of grade 3-4 events was similar for patients treated with ruxolitinib or reference treatments (4.7% versus 3.1%). Most of the patients with bleeding events during the treatment reported bruising (65.3%). Bruising events were more frequently reported in patients taking ruxolitinib compared with the reference treatments (21.3% versus 11.6%). Intracranial bleeding was reported in 1% of patients exposed to ruxolitinib and 0.9% exposed to reference treatments. Gastrointestinal bleeding was reported in 5.0% of patients exposed to ruxolitinib compared to 3.1% exposed to reference treatments. Other bleeding events (including events such as epistaxis, post-procedural haemorrhage and haematuria) were reported in 13.3% of patients treated with ruxolitinib and 10.3% treated with reference treatments.</p><p>&nbsp;</p><p>During the long-term follow-up of phase 3 clinical studies in MF, the cumulative frequency of bleeding events increased proportionally to the increase in the follow-up time. Bruising events were the most frequently reported bleeding events (33.3%). Intracranial and gastrointestinal bleeding events were reported in 1.3% and 10.1% of patients respectively.</p><p>&nbsp;</p><p>In the comparative period of phase 3 studies in PV patients, bleeding events (including intracranial and gastrointestinal, bruising and other bleeding events) were reported in 16.8% of patients treated with ruxolitinib, 15.3% of patients receiving best available therapy in RESPONSE study and 12.0% of patients receiving best available therapy in RESPONSE 2 study. Bruising was reported in 10.3% of patients treated with ruxolitinib, 8.1% of patients receiving best available therapy in RESPONSE study and 2.7% of patients receiving best available therapy in RESPONSE 2 study. No intracranial bleeding or gastrointestinal haemorrhage events were reported in patients receiving ruxolitinib. One patient treated with ruxolitinib experienced a grade 3 bleeding event (post-procedural bleeding); no grade 4 bleeding was reported. Other bleeding events (including events such as epistaxis, post-procedural haemorrhage, gingival bleeding) were reported in 8.7% of patients treated with ruxolitinib, 6.3% of patients treated with best available therapy in RESPONSE study and 6.7% of patients treated with best available therapy in RESPONSE 2 study.</p><p>&nbsp;</p><p>During the long-term follow-up of phase 3 studies in PV, the cumulative frequency of bleeding events increased proportionally to the increase in the follow-up time. Bruising events were the most frequently reported bleeding events (17.4%). Intracranial and gastrointestinal bleeding events were reported in 0.3% and 3.5% of patients respectively.</p><p>&nbsp;</p><p><u>Infections</u></p><p>In the phase 3 pivotal studies in MF, grade 3 or 4 urinary tract infection was reported in 1.0% of patients, herpes zoster in 4.3% and tuberculosis in 1.0%. In phase 3 clinical studies sepsis was reported in 3.0% of patients. An extended follow-up of patients treated with ruxolitinib showed no trends towards an increase in the rate of sepsis over time.</p><p>&nbsp;</p><p>In the randomised period of the phase 3 studies in PV patients, one (0.5%) CTCAE grade 3 and no grade 4 urinary tract infection was reported. The rate of herpes zoster was similar in PV (4.3%) patients and MF (4.0%) patients. There was one report of CTCAE grade 3 post-herpetic neuralgia amongst the PV patients. Pneumonia was reported in 0.5% of patients treated with ruxolitinib compared to 1.6% of patients in reference treatments. No patients in the ruxolitinib arm reported sepsis or tuberculosis.</p><p>&nbsp;</p><p>During long-term follow-up of phase 3 studies in PV, frequently reported infections were urinary tract infections (11.8%), herpes zoster (14.7%) and pneumonia (7.1%). Sepsis was reported in 0.6% of patients. No patients reported tuberculosis in long-term follow-up.</p><p>&nbsp;</p><p>In the phase 2 acute GvHD study (REACH1), Grade 3 CMV infections were reported in 8.5% (no Grade 4 event). CMV infection with organ involvement was seen in one patient who reported CMV chorioretinitis (grade 3).</p><p>&nbsp;</p><p>Sepsis events including septic shock of any Grade were reported in 22.5% of patients.</p><p>In the phase 3 acute GvHD study, grade 3 and 4 CMV infections were reported in 10.9% and 0.5% of patients, respectively. CMV infection with organ involvement was seen in very few patients; CMV colitis, CMV enteritis and CMV gastrointestinal infection of any grade were reported in four, two and one patients, respectively.</p><p>&nbsp;</p><p>Sepsis events including septic shock of any grade were reported in 25.4% of patients.</p><p>&nbsp;</p><p>In the phase 3 chronic GvHD study, grade 3 urinary tract infections and BK virus infections were reported in 1.3% and 0.4% of patients, respectively.</p><p>&nbsp;</p><p><u>Elevated lipase</u></p><p>In the randomised period of the RESPONSE study, the worsening of lipase values was higher in the ruxolitinib arm compared to the control arm, mainly due to the differences among grade 1 elevations (18.2% vs 8.1%). Grade &ge;2 elevations were similar between treatment arms. In RESPONSE 2, the frequencies were comparable between the ruxolitinib and the control arm (10.8% vs 8%). During long-term follow-up of phase 3 PV studies, 7.4% and 0.9% of patients reported grade 3 and grade 4 elevation of lipase values. No concurrent signs and symptoms of pancreatitis with elevated lipase values were reported in these patients.</p><p>&nbsp;</p><p>In phase 3 studies in MF, high lipase values were reported in 18.7% and 19.3% of patients in the ruxolitinib arms compared to 16.6% and 14.0% in the control arms in COMFORT-I and COMFORT-II studies, respectively. In patients with elevated lipase values, no concurrent signs and symptoms of pancreatitis were reported.</p><p>&nbsp;</p><p>In the phase 3 chronic GvHD study, grade 3 and 4 increased lipase was observed in 9.5% and 0.4% of patients, respectively.</p><p>&nbsp;</p><p><u>Increased systolic blood pressure</u></p><p>In the phase 3 pivotal clinical studies in MF an increase in systolic blood pressure of 20 mmHg or more from baseline was recorded in 31.5% of patients on at least one visit compared with 19.5% of the control-treated patients. In COMFORT-I (MF patients) the mean increase from baseline in systolic BP was 0-2 mmHg on ruxolitinib versus a decrease of 2-5 mmHg in the placebo arm. In COMFORT-II mean values showed little difference between the ruxolitinib-treated and the control-treated MF patients.</p><p>&nbsp;</p><p>In the randomised period of the pivotal study in PV patients, the mean systolic blood pressure increased by 0.65 mmHg in the ruxolitinib arm versus a decrease of 2 mmHg in the BAT arm.</p><p>&nbsp;</p><p><strong>Reporting of suspected adverse reactions</strong></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><ul><li>&nbsp; &nbsp; Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><ul><li>&nbsp; &nbsp; Other GCC States</li></ul><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no known antidote for overdoses with ruxolitinib. Single doses up to 200 mg have been given with acceptable acute tolerability. Higher than recommended repeat doses are associated with increased myelosuppression including leukopenia, anaemia and thrombocytopenia. Appropriate supportive treatment should be given.</p><p>&nbsp;</p><p>Haemodialysis is not expected to enhance the elimination of ruxolitinib.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antineoplastic agents, protein kinase inhibitors, ATC code: L01XE18.</p><p>&nbsp;</p><p><strong>Mechanism of action</strong></p><p>Ruxolitinib is a selective inhibitor of the Janus Associated Kinases (JAKs) JAK1 and JAK2 (IC50 values of 3.3 nM and 2.8 nM for JAK1 and JAK2 enzymes, respectively). These mediate the signalling of a number of cytokines and growth factors that are important for haematopoiesis and immune function.</p><p>&nbsp;</p><p>MF and PV are myeloproliferative neoplasms known to be associated with dysregulated JAK1 and JAK2 signalling. The basis for the dysregulation is believed to include high levels of circulating cytokines that activate the JAK-STAT pathway, gain-of-function mutations such as JAK2V617F, and silencing of negative regulatory mechanisms. MF patients exhibit dysregulated JAK signalling regardless of JAK2V617F mutation status. Activating mutations in JAK2 (V617F or exon 12) are found in &gt;95% of PV patients.</p><p>&nbsp;</p><p>Ruxolitinib inhibits JAK-STAT signalling and cell proliferation of cytokine-dependent cellular models of haematological malignancies, as well as of Ba/F3 cells rendered cytokine-independent by expressing the JAK2V617F mutated protein, with IC50 ranging from 80-320 nM.</p><p>&nbsp;</p><p>JAK-STAT signalling pathways play a role in regulating the development, proliferation, and activation of several immune cell types important for GvHD pathogenesis.</p><p>&nbsp;</p><p><strong>Pharmacodynamic effects</strong></p><p>Ruxolitinib inhibits cytokine-induced STAT3 phosphorylation in whole blood from healthy subjects, MF patients and PV patients. Ruxolitinib resulted in maximal inhibition of STAT3 phosphorylation 2 hours after dosing which returned to near baseline by 8 hours in both healthy subjects and MF patients, indicating no accumulation of either parent or active metabolites.</p><p>&nbsp;</p><p>Baseline elevations in inflammatory markers associated with constitutional symptoms such as TNF&alpha;, IL-6 and CRP in subjects with MF were decreased following treatment with ruxolitinib. MF patients did not become refractory to the pharmacodynamic effects of ruxolitinib treatment over time. Similarly, patients with PV also presented with baseline elevations in inflammatory markers and these markers were decreased following treatment with ruxolitinib.</p><p>&nbsp;</p><p>In a thorough QT study in healthy subjects, there was no indication of a QT/QTc prolonging effect of ruxolitinib in single doses up to a supratherapeutic dose of 200 mg, indicating that ruxolitinib has no effect on cardiac repolarisation.</p><p>&nbsp;</p><p><strong>Clinical efficacy and safety</strong></p><p><u>Myelofibrosis</u></p><p>Two randomised phase 3 studies (COMFORT-I and COMFORT-II) were conducted in patients with MF (primary MF, post-polycythaemia vera MF or post-essential thrombocythaemia MF). In both studies, patients had palpable splenomegaly at least 5 cm below the costal margin and risk category of intermediate-2 or high risk based on the International Working Group (IWG) Consensus Criteria. The starting dose of ruxolitinib was based on platelet count. Patients with platelet counts &le;100,000/mm<sup>3</sup> were not eligible for enrolment in COMFORT studies but 69 patients were enrolled in the EXPAND study, a Phase Ib, open label, dose-finding study in patients with MF (primary MF, post-polycythaemia vera MF or post-essential thrombocythaemia MF) and baseline platelet counts &ge;50,000 and &lt;100,000/mm<sup>3</sup>.</p><p>&nbsp;</p><p>COMFORT-I was a double-blind, randomised, placebo-controlled study in 309 patients who were refractory to or were not candidates for available therapy. The primary efficacy endpoint was proportion of subjects achieving &ge;35% reduction from baseline in spleen volume at week 24 as measured by Magnetic Resonance Imaging (MRI) or Computed Tomography (CT).</p><p>&nbsp;</p><p>Secondary endpoints included duration of maintenance of a &ge;35% reduction from baseline in spleen volume, proportion of patients who had &ge;50% reduction in total symptom score, changes in total symptom scores from baseline to week 24, as measured by the modified MF Symptom Assessment Form (MFSAF) v2.0 diary, and overall survival.</p><p>COMFORT-II was an open-label, randomised study in 219 patients. Patients were randomised 2:1 to ruxolitinib versus best available therapy. In the best available therapy arm, 47% of patients received hydroxyurea and 16% of patients received glucocorticoids. The primary efficacy endpoint was proportion of patients achieving &ge;35% reduction from baseline in spleen volume at week 48 as measured by MRI or CT.</p><p>&nbsp;</p><p>Secondary endpoints included proportion of patients achieving a &ge;35% reduction of spleen volume from baseline at week 24 and duration of maintenance of a &ge;35% reduction from baseline spleen volume.</p><p>&nbsp;</p><p>In COMFORT-I and COMFORT-II, patient baseline demographics and disease characteristics were comparable between the treatment arms.</p><p>&nbsp;</p><p><strong>Table 7 Percentage of patients with &ge;35% reduction from baseline in spleen volume at week 24 in COMFORT-I and at week 48 in COMFORT-II (ITT)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td colspan="2" style="vertical-align:top"><p><strong>COMFORT-I</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>COMFORT-II</strong></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Ruxolitinib &nbsp;</p><p>(N=155)</p></td><td style="vertical-align:top"><p>Placebo</p><p>(N=153)</p></td><td style="vertical-align:top"><p>Ruxolitinib &nbsp;</p><p>(N=144)</p></td><td style="vertical-align:top"><p>Best available therapy</p><p>(N=72)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Time points</strong></p></td><td colspan="2" style="vertical-align:top"><p>Week 24</p></td><td colspan="2" style="vertical-align:top"><p>Week 48</p></td></tr><tr><td style="vertical-align:top"><p><strong>Number (%) of subjects with spleen volume reduced by &ge;35%</strong></p></td><td style="vertical-align:top"><p>65 (41.9)</p></td><td style="vertical-align:top"><p>1 (0.7)</p></td><td style="vertical-align:top"><p>41 (28.5)</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p><strong>95% confidence intervals</strong></p></td><td style="vertical-align:top"><p>34.1, 50.1</p></td><td style="vertical-align:top"><p>0, 3.6</p></td><td style="vertical-align:top"><p>21.3, 36.6</p></td><td style="vertical-align:top"><p>0.0, 5.0</p></td></tr><tr><td style="vertical-align:top"><p><strong>p-value</strong></p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.0001</p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.0001</p></td></tr></tbody></table><p>&nbsp;</p><p>A significantly higher proportion of patients in the ruxolitinib group achieved &ge;35% reduction from baseline in spleen volume (Table 7) regardless of the presence or absence of the JAK2V617F mutation or the disease subtype (primary MF, post-polycythaemia vera MF, post-essential thrombocythaemia MF).</p><p>&nbsp;</p><p><strong>Table 8 Percentage of patients with &ge;35% reduction from baseline in spleen volume by JAK mutation status (safety set) </strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td colspan="4" style="vertical-align:top"><p><strong>COMFORT-I</strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>COMFORT-II</strong></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td colspan="2" style="vertical-align:top"><p>Ruxolitinib</p></td><td colspan="2" style="vertical-align:top"><p>Placebo</p></td><td colspan="2" style="vertical-align:top"><p>Ruxolitinib</p></td><td colspan="2" style="vertical-align:top"><p>Best available therapy</p></td></tr><tr><td style="vertical-align:top"><p>JAK mutation status</p></td><td style="vertical-align:top"><p>Positive</p><p>(N=113)</p><p>n (%)</p></td><td style="vertical-align:top"><p>Negative</p><p>(N=40)</p><p>n (%)</p></td><td style="vertical-align:top"><p>Positive</p><p>(N=121)</p><p>n (%)</p></td><td style="vertical-align:top"><p>Negative</p><p>(N=27)</p><p>n (%)</p></td><td style="vertical-align:top"><p>Positive</p><p>(N=110)</p><p>n (%)</p></td><td style="vertical-align:top"><p>Negative</p><p>(N=35)</p><p>n (%)</p></td><td style="vertical-align:top"><p>Positive</p><p>(N=49)</p><p>n (%)</p></td><td style="vertical-align:top"><p>Negative</p><p>(N=20)</p><p>n (%)</p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of subjects with spleen volume reduced by &ge;35%</p></td><td style="vertical-align:top"><p>54</p><p>(47.8)</p></td><td style="vertical-align:top"><p>11</p><p>(27.5)</p></td><td style="vertical-align:top"><p>1</p><p>(0.8)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>36</p><p>(32.7)</p></td><td style="vertical-align:top"><p>5</p><p>(14.3)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Time point</p></td><td colspan="4" style="vertical-align:top"><p>After 24 weeks</p></td><td colspan="4" style="vertical-align:top"><p>After 48 weeks</p></td></tr></tbody></table><p>&nbsp;</p><p>The probability of maintaining spleen response (&ge;35% reduction) to ruxolitinib for at least 24 weeks was 89% in COMFORT-I and 87% in COMFORT-II; 52% maintained spleen responses for at least 48 weeks in COMFORT-II.</p><p>&nbsp;</p><p>In COMFORT-I, 45.9% subjects in the ruxolitinib group achieved a &ge;50% improvement from baseline in the week 24 total symptom score (measured using MFSAF diary v2.0), as compared to 5.3% in the placebo group (p&lt;0.0001 using chi-square test). The mean change in the global health status at week 24, as measured by EORTC QLQ C30 was +12.3 for ruxolitinib and -3.4 for placebo (p&lt;0.0001).</p><p>&nbsp;</p><p>In COMFORT-I, after a median follow-up of 34.3 months, the death rate in patients randomised to the ruxolitinib arm was 27.1% versus 35.1% in patients randomised to placebo; HR 0.687; 95% CI 0.459-1.029; p=0.0668.</p><p>&nbsp;</p><p>In COMFORT-I, after a median follow&ndash;up of 61.7 months, the death rate in patients randomised to the ruxolitinib arm was 44.5% (69 of 155 patients) versus 53.2% (82 of 154) in patients randomised to placebo. There was a 31% reduction in the risk of death in the ruxolitinib arm as compared to placebo (HR 0.69; 95% CI 0.50-0.96; p=0.025).</p><p>&nbsp;</p><p>In COMFORT-II, after a median follow-up of 34.7 months, the death rate in patients randomised to ruxolitinib was 19.9% versus 30.1% in patients randomised to best available treatment (BAT); HR 0.48; 95% CI 0.28-0.85; p=0.009. In both studies, the lower death rates noted in the ruxolitinib arm were predominantly driven by the results obtained in the post polycythaemia vera and post essential thrombocythaemia subgroups.</p><p>&nbsp;</p><p>In COMFORT-II, after a median follow-up of 55.9 months, the death rate in patients randomised to the ruxolitinib arm was 40.4% (59 of 146 patients) versus 47.9% (35 of 73 patients) in patients randomized to best available therapy (BAT). There was a 33% reduction in risk of death in the ruxolitinib arm compared to the BAT arm (HR 0.67; 95% CI 0.44-1.02; p=0.062).</p><p>&nbsp;</p><p><u>Polycythaemia vera</u></p><p>A randomised, open-label, active-controlled phase 3 study (RESPONSE) was conducted in 222 patients with PV who were resistant to or intolerant of hydroxyurea defined based on the European LeukemiaNet (ELN) international working group published criteria. 110 patients were randomised to the ruxolitinib arm and 112 patients to the BAT arm. The starting dose of ruxolitinib was 10 mg twice daily. Doses were then adjusted in individual patients based on tolerability and efficacy with a maximum dose of 25 mg twice daily. BAT was selected by the investigator on a patient-by-patient basis and included hydroxyurea (59.5%), interferon/pegylated interferon (11.7%), anagrelide (7.2%), pipobroman (1.8%) and observation (15.3%).</p><p>&nbsp;</p><p>Baseline demographics and disease characteristics were comparable between the two treatments arms. The median age was 60 years (range 33 to 90 years). Patients in the ruxolitinib arm had PV diagnosis for a median of 8.2 years and had previously received hydroxyurea for a median of approximately 3 years. Most patients (&gt;80%) had received at least two phlebotomies in the last 24 weeks prior to screening. Comparative data regarding long-term survival and incidence of disease complications is missing.</p><p>&nbsp;</p><p>The primary composite endpoint was the proportion of patients achieving both an absence of phlebotomy eligibility (HCT control) and a &ge;35% reduction in spleen volume from baseline at week 32. Phlebotomy eligibility was defined as a confirmed HCT of &gt;45%, i.e. at least 3 percentage points higher than the HCT obtained at baseline or a confirmed HCT of &gt;48%, depending on which was lower. Key secondary endpoints included the proportion of patients who achieved the primary endpoint and remained free from progression at week 48, as well as the proportion of patients achieving complete haematological remission at week 32.</p><p>&nbsp;</p><p>The study met its primary objective and a higher proportion of patients in the ruxolitinib group achieved the primary composite endpoint and each of its individual components. Significantly more patients treated with ruxolitinib (23%) achieved a primary response (p&lt;0.0001) compared to BAT (0.9%). Haematocrit control was achieved in 60% of patients in the ruxolitinib arm compared to 18.8% in the BAT arm and a &ge;35% reduction in spleen volume was achieved in 40% of patients in the ruxolitinib arm compared to 0.9% in the BAT arm (Figure 1).</p><p>&nbsp;</p><p>Both key secondary endpoints were also met. The proportion of patients achieving a complete haematological remission was 23.6% on ruxolitinib compared to 8.0% on BAT (p=0.0013) and the proportion of patients achieving a durable primary response at week 48 was 20% on ruxolitinib and 0.9% on BAT (p&lt;0.0001).</p><p>&nbsp;</p><p><strong>Figure 1 Patients achieving the primary endpoint and components of the primary endpoint at week 32</strong></p><p>&nbsp;<img alt="" width="603" height="306" src="data:image/png;base64,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" /><strong> </strong></p><p>Symptom burden was assessed using the MPN-SAF total symptom score (TSS) electronic patient diary, which consisted of 14 questions. At week 32, 49% and 64% of patients treated with ruxolitinib achieved a &ge;50% reduction in TSS-14 and TSS-5, respectively, compared to only 5% and 11% of patients on BAT.</p><p>&nbsp;</p><p>Treatment benefit perception was measured by the Patient Global Impression of Change (PGIC) questionnaire. 66% of patients treated with ruxolitinib compared to 19% treated with BAT reported an improvement as early as four weeks after beginning treatment. Improvement in perception of treatment benefit was also higher in patients treated with ruxolitinib at week 32 (78% versus 33%).</p><p>&nbsp;</p><p>Additional analyses from the RESPONSE study to assess durability of response were conducted at week 80 and week 256 following randomisation. Out of 25 patients who had achieved primary response at week 32, 3 patients had progressed by week 80 and 6 patients by week 256. The probability to have maintained a response from week 32 up to week 80 and week 256 was 92% and 74%, respectively (see Table 9).</p><p>&nbsp;</p><p><strong>Table 9 Durability of primary response in the RESPONSE study</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p><strong>Week 32</strong></p></td><td style="vertical-align:top"><p><strong>Week 80</strong></p></td><td style="vertical-align:top"><p><strong>Week 256</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Primary response achieved at week 32*</strong></p><p><strong>n/N (%)</strong></p></td><td style="vertical-align:top"><p>25/110 (23%)</p></td><td style="vertical-align:top"><p>n/a</p></td><td style="vertical-align:top"><p>n/a</p></td></tr><tr><td style="vertical-align:top"><p><strong>Patients maintaining primary response</strong></p></td><td style="vertical-align:top"><p>n/a</p></td><td style="vertical-align:top"><p>22/25</p></td><td style="vertical-align:top"><p>19/25</p></td></tr><tr><td style="vertical-align:top"><p><strong>Probability of maintaining primary response</strong></p></td><td style="vertical-align:top"><p>n/a</p></td><td style="vertical-align:top"><p>92%</p></td><td style="vertical-align:top"><p>74%</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>* According to the primary response composite endpoint criteria: absence of phlebotomy eligibility (HCT control) and a &ge;35% reduction in spleen volume from baseline.</p><p>n/a: not applicable</p></td></tr></tbody></table><p>&nbsp;</p><p>A second randomised, open label, active-controlled phase 3b study (RESPONSE 2) was conducted in 149 PV patients who were resistant to, or intolerant of, hydroxyurea but without palpable splenomegaly. The primary endpoint defined as the proportion of patients achieving HCT control (absence of phlebotomy eligibility) at week 28 was met (62.2% in the ruxolitinib arm versus 18.7% in the BAT arm). The key secondary endpoint defined as the proportion of patients achieving complete haematological remission at week 28 was also met (23.0% in the ruxolitinib arm versus 5.3% in the BAT arm).</p><p>&nbsp;</p><p><u>Graft-versus-host disease</u></p><p><em>Acute graft-versus-host disease</em></p><p>In REACH-1, 71 patients (&ge; 12 years) with grade II to IV corticosteroid-refractory acute GvHD (Mount Sinai Acute GvHD International Consortium (MAGIC) criteria) received open-label ruxolitinib at a dose of 5 mg twice daily. Corticosteroid refractoriness was determined when patients had progression after at least 3 days, failed to achieve a response after 7 days or failed corticosteroid taper.</p><p>&nbsp;</p><p>Participants began oral administration of ruxolitinib at 5 mg BID; if hematologic parameters were stable and no treatment-related toxicity was observed after the first 3 days of treatment, the dose could be increased to 10 mg BID.</p><p>&nbsp;</p><p>In addition to ruxolitinib, patients could have received standard allogeneic stem cell transplantation supportive care including anti-infective medicinal products and transfusion support.</p><p>&nbsp;</p><p>At baseline, acute GvHD was grade II in 31.0%, Grade III in 46.5%, and Grade IV in 22.5%. Approximately half of the participants (52.1%) had at least 2 organs involved at baseline with distribution across the lower GI tract (71.8%), skin (50.7%), upper GI tract (31.0%), and liver (22.5%).71.8% had lower GI-tract and skin (50.7% involvement). Majority (80.3%) of them had peripheral blood stem cell (PBSC) transplants and from identical HLA-matched donors (63.4%).</p><p>&nbsp;</p><p>The median time since alloSCT was 74.0 days, and the median time since acute GvHD diagnosis was 17.0 days. The median duration of study treatment as of the final analysis data cut-off date (05-Jun-2019) was 46.0 days, and 18 patients (25.4%) received ruxolitinib for more than 180 days.</p><p>&nbsp;</p><p>The median age of participants was 58 years (range: 18-73 years), 49.3% were males and 50.7% were females, and 93.0% of participants were white/Caucasian. Approximately 60.6% of the participants had baseline ECOG performance status of 2 or higher, with 25.4% at 3 or higher.</p><p>&nbsp;</p><p>All 71 participants had received prior systemic therapy with corticosteroids for the treatment of GVHD. The median duration of prior corticosteroid exposure was 16.0 days, and the median average daily dose of corticosteroids at the start of study treatment was 156.25 mg/day. In addition to prior corticosteroid treatment, 23.9% of participants had received calcineurin inhibitors, with or without methotrexate). The most common reasons for discontinuation of the most recent prior acute GVHD therapy were PD and lack of efficacy.</p><p>&nbsp;</p><p>The primary endpoint of REACH1 was the overall response rate (ORR) on Day 28, defined as the proportion of patients in each arm with a complete response (CR), very good partial response (VGPR) or a partial response (PR) as per the CIBMTR modifications to the IBMTR response index.</p><p>The REACH 1 study achieved the predetermined threshold for a positive study outcome (lower limit of the 95% CI for Day 28 ORR &ge; 40%). Forty participants (56.3% [95% CI: 44.0, 68.1]) demonstrated a response at Day 28, including 19 participants (26.8%) who achieved a CR, 6 participants who achieved a VGPR (8.5%) and 15 participants who achieved a PR (21.1%). Of the participants who had a response on Day 28, 19 of 40 participants had a CR (26.8%). The best ORR, defined as the proportion of participants demonstrating a response at any timepoint, was 76.1% (95% CI: 64.5, 85.4). The majority of participants (62.0%) achieved their first response within the first 14 days of treatment, with a median time to first response of 8 days; all first responses were achieved before Day 56.</p><p>&nbsp;</p><p><strong>Table 10 Day-28 Overall response rate</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p><strong>Ruxolitinib (N=71)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Overall Response (%) (95% CI)</strong></p></td><td style="vertical-align:top"><p>40 (56.3) (44.0, 68.1)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Complete Response</strong></p></td><td style="vertical-align:top"><p>19 (26.8%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Very Good Partial Response</strong></p></td><td style="vertical-align:top"><p>6 (8.5%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Partial Response</strong></p></td><td style="vertical-align:top"><p>15 (21.1%)</p></td></tr></tbody></table><p>&nbsp;</p><p>The REACH2 study evaluated 309 patients with grade II to IV corticosteroid-refractory, acute GvHD were randomised 1:1 to ruxolitinib or BAT. Patients were stratified by severity of acute GvHD at the time of randomisation. Corticosteroid refractoriness was determined when patients had progression after at least 3 days, failed to achieve a response after 7 days or failed corticosteroid taper.</p><p>&nbsp;</p><p>Ruxolitinib was administered orally twice per day at a dose of 10 mg bid.</p><p>&nbsp;</p><p>BAT was selected by the investigator on a patient-by-patient basis and included anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), mesenchymal stromal cells (MSC), low dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), etanercept, or infliximab.</p><p>&nbsp;</p><p>In addition to ruxolitinib or BAT, patients could have received standard allogeneic stem cell transplantation supportive care including anti-infective medicinal products and transfusion support. as well as standard acute GvHD prophylaxis and treatment medicinal products initiated before randomisation including systemic corticosteroids and calcineurin inhibitors (CNIs) such as cyclosporine or tacrolimus. Topical or inhaled corticosteroid therapies were allowed to be continued per institutional guidelines.</p><p>&nbsp;</p><p>Patients randomised to the BAT arm were allowed to cross over to the ruxolitinib arm after the day 28 visit, if they did not demonstrate complete or partial response at Day 28. Tapering of ruxolitinib was allowed after the day 56 visit for patients with treatment response.</p><p>&nbsp;</p><p>The safety data derived from the REACH 2 study is presented above in section 4.8.</p><p>&nbsp;</p><p><em>Chronic graft-versus-host disease</em></p><p>In REACH3, 329 patients with moderate or severe corticosteroid-refractory, chronic GVHD were randomised 1:1 to ruxolitinib or BAT. Patients were stratified by severity of chronic GVHD at the time of randomisation. Corticosteroid refractoriness was determined when patients had lack of response or disease progression after 7 days, or had disease persistence for 4 weeks or failed corticosteroid taper twice.</p><p>&nbsp;</p><p>BAT was selected by the investigator on a patient-by-patient basis and included extracorporeal photopheresis (ECP), low dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), infliximab, rituximab, pentostatin, imatinib, or ibrutinib.</p><p>&nbsp;</p><p>Patients were allowed to have received allogeneic stem cell transplantation (SCT) from any donor source and with any conditioning regimen. In addition to ruxolitinib or BAT, patients could have received standard allogeneic SCT supportive care including anti-infective medicinal products and transfusion support. Continued use of corticosteroids and CNIs such as cyclosporine or tacrolimus and topical or inhaled corticosteroid therapies were allowed per institutional guidelines.</p><p>&nbsp;</p><p>Patients who received one prior systemic treatment other than corticosteroids and CNIs for chronic GvHD were eligible for inclusion in the study. In addition to corticosteroids and CNIs, prior systemic medicinal product for chronic GvHD was allowed to continue only if used for chronic GvHD prophylaxis (i.e. started before the chronic GvHD diagnosis) as per common medical practice.</p><p>&nbsp;</p><p>Patients on BAT not achieving partial response or better, could cross over to ruxolitinib on cycle 7 day 1 and thereafter.</p><p>&nbsp;</p><p>Tapering of ruxolitinib was allowed after the cycle 7 day 1 visit.</p><p>&nbsp;</p><p>Baseline demographics and disease characteristics were balanced between the two treatment arms. The median age was 49 years (range 12 to 76 years). The study included 3.6% adolescent, 61.1% male and 75.4% white patients. The majority of enrolled patients had malignant underlying disease.</p><p>&nbsp;</p><p>The severity at diagnosis of corticosteroid-refractory chronic GVHD was balanced between the two treatment arms, with 41% and 45% moderate, and 59% and 55% severe, in the ruxolitinib and the BAT arms, respectively.</p><p>&nbsp;</p><p>The reasons for patients&#39; insufficient response to corticosteroids in the ruxolitinib and BAT arm were i) a lack of response or disease progression after corticosteroid treatment for at least 7 days at 1 mg/kg/day of prednisone equivalents (37.6% and 44.5%, respectively), ii) disease persistence after 4 weeks at 0.5 mg/kg/day (35.2% and 25.6%), or iii) corticosteroid dependency (27.3% and 29.9%, respectively).</p><p>&nbsp;</p><p>Among all patients, 73% and 45% had skin and lung involvement in the ruxolitinib arm, compared to 69% and 41% in the BAT arm.</p><p>&nbsp;</p><p>The most frequently used prior systemic chronic GVHD therapies were corticosteroids only (43% in the ruxolitinib arm and 49% in the BAT arm) and corticosteroids+CNIs (41% patients in the ruxolitinib arm and 42% in the BAT arm).</p><p>&nbsp;</p><p>The primary endpoint was the ORR on day 1 of cycle 7, defined as the proportion of patients in each arm with a CR or a PR without the requirement of additional systemic therapies for an earlier progression, mixed response or non-response based on investigator assessment per National Institute of Health (NIH) criteria.</p><p>&nbsp;</p><p>Key secondary endpoints were failure free survival (FFS) and proportion of patients with improvement of the modified Lee symptoms score (mLSS) at cycle 7 day 1. FFS, a composite time to event endpoint, incorporated the earliest of the following events: i) relapse or recurrence of underlying disease or death due to underlying disease, ii) non-relapse mortality, or iii) addition or initiation of another systemic therapy for chronic GVHD.</p><p>REACH3 met its primary objective. At the time of primary analysis (data cut-off data: 08-May-2020), the ORR at week 24 was higher in the ruxolitinib arm (49.7%) compared to the BAT arm (25.6%). There was a statistically significant difference between the treatment arms (stratified Cochrane-Mantel-Haenszel test p&lt;0.0001, one-sided, OR: 2.99; 95% CI: 1.86, 4.80). Results are presented in Table 11.</p><p>&nbsp;</p><p>Among the non-responders at cycle 7 day 1 in the ruxolitinib and BAT arms, 2.4% and 12.8% had disease progression, respectively.&nbsp;</p><p><strong>Table 11 Overall response rate at cycle 7 day 1 in REACH3</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td colspan="2" style="vertical-align:top"><p><strong>Ruxolitinib</strong><strong>&nbsp; </strong></p><p><strong>N=165</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>BAT</strong></p><p><strong>N=164</strong></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>n (%)</p></td><td style="vertical-align:top"><p>95% CI</p></td><td style="vertical-align:top"><p>n (%)</p></td><td style="vertical-align:top"><p>95% CI</p></td></tr><tr><td style="vertical-align:top"><p><strong>Overall response</strong></p></td><td style="vertical-align:top"><p>82 (49.7)</p></td><td style="vertical-align:top"><p>41.8, 57.6</p></td><td style="vertical-align:top"><p>42 (25.6)</p></td><td style="vertical-align:top"><p>19.1, 33.0</p></td></tr><tr><td style="vertical-align:top"><p><strong>OR (95% CI)</strong></p></td><td colspan="4" style="vertical-align:top"><p>2.99 (1.86, 4.80)</p></td></tr><tr><td style="vertical-align:top"><p><strong>p-value</strong></p></td><td colspan="4" style="vertical-align:top"><p>p&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p><strong>Complete response</strong></p></td><td colspan="2" style="vertical-align:top"><p>11 (6.7)</p></td><td colspan="2" style="vertical-align:top"><p>5 (3.0)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Partial response</strong></p></td><td colspan="2" style="vertical-align:top"><p>71 (43.0)</p></td><td colspan="2" style="vertical-align:top"><p>37 (22.6)</p></td></tr></tbody></table><p>&nbsp;</p><p>The key secondary endpoint, FFS, demonstrated a statistically significant 63% risk reduction of ruxolitinib versus BAT (HR: 0.370; 95% CI: 0.268, 0.510, p&lt;0.0001). Prior to crossover, the 5-months FFS probability (95% CI) was 78.1% (70.9%, 83.7%) and 62.7% (54.6%, 69.7%) for the ruxolitinib and BAT arms, respectively. The 6-months FFS probability (95% CI) was 74.9% (67.5%, 80.9%) and 44.5% (36.5%, 52.1%) for the ruxolitinib and BAT arms, respectively. At 6-months, the majority of FFS events were &ldquo;addition or initiation of another systemic therapy for chronic GvVHD&rdquo; (probability of that event was 13.5% and 48.5% for the ruxolitinib and BAT arms, respectively). Results for &ldquo;relapse of underlying disease&rdquo; and non-relapse mortality (NRM) were 2.46% vs 2.57% and 9.19% vs 4.46%, in the ruxolitinib and the BAT arms, respectively. No difference of cumulative incidences between treatment arms was observed when focusing on NRM only.</p><p>&nbsp;</p><p>The rate of responders as per improvement of &ge;7 points of total symptom score (TSS) from baseline of the mLSS showed a statistically significant difference (p=0.0011) between the ruxolitinib (24.2%) and BAT arms (11.0%).</p><p>&nbsp;</p><p><strong>Paediatric population</strong></p><p>The Medicines and Healthcare Products Regulatory Agency has waived the obligation to submit the results of studies with ruxolitinib in all subsets of the paediatric population for the treatment of MF and PV. In GvHD paediatric patients (12 years of age and older), the safety and efficacy of ruxolitinib are supported by evidence from the studies REACH1, REACH2 and REACH3 (see section 4.2 for information on paediatric use). In REACH2, responses were observed at day 28 in 4/5 adolescent patients with acute GvHD (3 had CR and 1 had PR) in the ruxolitinib arm and in 3/4 adolescent patients (3 had CR) in the BAT arm. In REACH3, responses were observed at cycle 7 day 1 in 3/4 adolescent patients with chronic GvHD (all had PR) in the ruxolitinib arm and in 2/8 adolescent patients (both had PR) in the BAT arm.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption</strong></p><p>Ruxolitinib is a Biopharmaceutical Classification System (BCS) class 1 compound, with high permeability, high solubility and rapid dissolution characteristics. In clinical studies, ruxolitinib is rapidly absorbed after oral administration with maximal plasma concentration (C<sub>max</sub>) achieved approximately 1 hour post-dose. Based on a human mass balance study, oral absorption of ruxolitinib, as ruxolitinib or metabolites formed under first-pass, is 95% or greater. Mean ruxolitinib C<sub>max</sub> and total exposure (AUC) increased proportionally over a single dose range of 5-200 mg. There was no clinically relevant change in the pharmacokinetics of ruxolitinib upon administration with a high-fat meal. The mean C<sub>max</sub> was moderately decreased (24%) while the mean AUC was nearly unchanged (4% increase) on dosing with a high-fat meal.</p><p>&nbsp;</p><p><strong>Distribution</strong></p><p>The mean volume of distribution at steady state is approximately 75 litres in MF and PV patients. At clinically relevant concentrations of ruxolitinib, binding to plasma proteins <em>in vitro</em> is approximately 97%, mostly to albumin. A whole body autoradiography study in rats has shown that ruxolitinib does not penetrate the blood-brain barrier.</p><p>&nbsp;</p><p><strong>Biotransformation</strong></p><p>Ruxolitinib is mainly metabolised by CYP3A4 (&gt;50%), with additional contribution from CYP2C9. Parent compound is the predominant entity in human plasma, representing approximately 60% of the drug-related material in circulation. Two major and active metabolites are present in plasma representing 25% and 11% of parent AUC. These metabolites have one half to one fifth of the parent JAK-related pharmacological activity. The sum total of all active metabolites contributes to 18% of the overall pharmacodynamics of ruxolitinib. At clinically relevant concentrations, ruxolitinib does not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 or CYP3A4 and is not a potent inducer of CYP1A2, CYP2B6 or CYP3A4 based on <em>in vitro</em> studies. In vitro data indicate that ruxolitinib may inhibit P-gp and BCRP.</p><p>&nbsp;</p><p><strong>Elimination</strong></p><p>Ruxolitinib is mainly eliminated through metabolism. The mean elimination half-life of ruxolitinib is approximately 3 hours. Following a single oral dose of [14C]-labelled ruxolitinib in healthy adult subjects, elimination was predominately through metabolism, with 74% of radioactivity excreted in urine and 22% via faeces. Unchanged parent substance accounted for less than 1% of the excreted total radioactivity.</p><p>&nbsp;</p><p><strong>Linearity/non-linearity</strong></p><p>Dose proportionality was demonstrated in the single and multiple dose studies.</p><p>&nbsp;</p><p><strong>Special populations</strong></p><p><em>Effects of age, gender or race</em></p><p>Based on studies in healthy subjects, no relevant differences in ruxolitinib pharmacokinetics were observed with regard to gender and race. In a population pharmacokinetic evaluation in MF patients, no relationship was apparent between oral clearance and patient age or race. The predicted oral clearance was 17.7 l/h in women and 22.1 l/h in men, with 39% inter-subject variability in MF patients. Clearance was 12.7 l/h in PV patients, with a 42% inter-subject variability and no relationship was apparent between oral clearance and gender, patient age or race, based on a population pharmacokinetic evaluation in PV patients. Clearance was 10.4 l/h in patients with acute GvHD and 7.8 l/h in patients with chronic GvHD, with a 49% inter-subject variability. No relationship was apparent between oral clearance and gender, patient age or race, based on a population pharmacokinetic evaluation in GvHD patients.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and effectiveness of ruxolitinib in paediatric patients with MF and PV have not been established the safety, efficacy and pharmacokinetic profile observed in adolescent patients with acute or chronic GvHD was comparable to the overall patient population (see section 5.1, &ldquo;Paediatric population&rdquo;).</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>Renal function was determined using both Modification of Diet in Renal Disease (MDRD) and urinary creatinine. Following a single ruxolitinib dose of 25 mg, the exposure of ruxolitinib was similar in subjects with various degrees of renal impairment and in those with normal renal function. However, plasma AUC values of ruxolitinib metabolites tended to increase with increasing severity of renal impairment, and were most markedly increased in the subjects with severe renal impairment. It is unknown whether the increased metabolite exposure is of safety concern. A dose modification is recommended in patients with severe renal impairment and end-stage renal disease (see section 4.2). Dosing only on dialysis days reduces the metabolite exposure, but also the pharmacodynamic effect, especially on the days between dialysis.</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>Following a single ruxolitinib dose of 25 mg in patients with varying degrees of hepatic impairment, the mean AUC for ruxolitinib was increased in patients with mild, moderate and severe hepatic impairment by 87%, 28% and 65%, respectively, compared to patients with normal hepatic function. There was no clear relationship between AUC and the degree of hepatic impairment based on Child-Pugh scores. The terminal elimination half-life was prolonged in patients with hepatic impairment compared to healthy controls (4.1-5.0 hours versus 2.8 hours). A dose reduction of approximately 50% is recommended for MF and PV patients with hepatic impairment (see section 4.2).</p><p>&nbsp;</p><p>In GvHD patients with hepatic impairment not related to GvHD, the starting dose of ruxolitinib should be reduced by 50%.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ruxolitinib has been evaluated in safety pharmacology, repeated dose toxicity, genotoxicity and reproductive toxicity studies and in a carcinogenicity study. Target organs associated with the pharmacological action of ruxolitinib in repeated dose studies include bone marrow, peripheral blood and lymphoid tissues. Infections generally associated with immunosuppression were noted in dogs. Adverse decreases in blood pressure along with increases in heart rate were noted in a dog telemetry study, and an adverse decrease in minute volume was noted in a respiratory study in rats. The margins (based on unbound C<sub>max</sub>) at the non-adverse level in the dog and rat studies were 15.7-fold and 10.4-fold greater, respectively, than the maximum human recommended dose of 25 mg twice daily. No effects were noted in an evaluation of the neuropharmacological effects of ruxolitinib.</p><p>&nbsp;</p><p>In juvenile rat studies, administration of ruxolitinib resulted in effects on growth and bone measures. Reduced bone growth was observed at doses &ge;5 mg/kg/day when treatment started on postnatal day 7 (comparable to human newborn) and at &ge;15 mg/kg/day when treatment started on postnatal days 14 or 21 (comparable to human infant, 1&ndash;3 years). Fractures and early termination of rats were observed at doses &ge;30 mg/kg/day when treatment was started on postnatal day 7. Based on unbound AUC, the exposure at the NOAEL (no observed adverse effect level) in juvenile rats treated as early as postnatal day 7 was 0.3-fold that of adult patients at 25 mg twice daily, while reduced bone growth and fractures occurred at exposures that were 1.5- and 13-fold that of adult patients at 25 mg twice daily, respectively. The effects were generally more severe when administration was initiated earlier in the postnatal period. Other than bone development, the effects of ruxolitinib in juvenile rats were similar to those in adult rats. Juvenile rats are more sensitive than adult rats to ruxolitinib toxicity.</p><p>&nbsp;</p><p>Ruxolitinib decreased foetal weight and increased post-implantation loss in animal studies. There was no evidence of a teratogenic effect in rats and rabbits. However, the exposure margins compared to the highest clinical dose were low and the results are therefore of limited relevance for humans. No effects were noted on fertility. In a pre- and post-natal development study, a slightly prolonged gestation period, reduced number of implantation sites, and reduced number of pups delivered were observed. In the pups, decreased mean initial body weights and short period of decreased mean body weight gain were observed. In lactating rats, ruxolitinib and/or its metabolites were excreted into the milk with a concentration that was 13-fold higher than the maternal plasma concentration. Ruxolitinib was not mutagenic or clastogenic. Ruxolitinib was not carcinogenic in the Tg.rasH2 transgenic mouse model.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp; Lactose</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Microcrystalline cellulose</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Hydroxypropyl cellulose</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Povidone</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Sodium starch glycolate</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Colloidal silicon dioxide</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Magnesium stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C. &nbsp;</p><p>&nbsp;</p><p>Store in the original package.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aluminum-aluminum blisters.</p><p>&nbsp;</p><p>Pack size: 56 Tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries
Al-Kharj Road 
P.O. Box 106229
Riyadh 11666, Saudi Arabia
Tel: + (966-11) 8107023, + (966-11) 2142472
Fax: + (966-11) 2078170
e-mail: SAPV@hikma.com  

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                30 November 2022 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>